



GENETIC RISK FACTORS IN 










   Supervisors:  Dr. János Kálmán 







Department of Psychiatry 
Albert Szent-Györgyi Clinical Center 








Articles the Thesis is based on 
 
Fehér Á, Juhász A, Rimanóczy Á, Kálmán J, Janka Z. Association between BDNF Val66Met 
Polymorphism and Alzheimer’s Disease, Dementia with Lewy Bodies and Pick’s Disease. 
Azheimer’s Disease and Associated Disorders. 2009. 23(3):224-228. IF2008: 3.220 
Fehér Á, Juhász A, Rimanóczy Á, Csibri É, Kálmán J, Janka Z. Association between a genetic 
variant of the alpha-7 nicotinic acetylcholine receptor subunit and four types of dementia. 
Dementia and Geriatric Cognitive Disorders. 2009. 28(1): 56-61. IF2008: 3.142 
 
Selected abstracts related to the thesis: 
 
A Juhász, Á Rimanóczy, Á Fehér, J Kálmán, M Gálfi, Z Janka. Alpha-7 nicotinic acetylcholine 
receptor and apolipoprotein E polymorphisms in Alzheimer’s dementia. The Journal of the 
European College of Neuropsychopharmacology. Vol. 17, Suppl. 4, p. S417; IF2007: 3.794 (20th 
Congress of European College of Neuropsychopharmacology, Vienna, Austria, 2007) 
A Juhász, Á Rimanóczy, Á Fehér, J Kálmán, Z Janka. Apolipoprotein E and cyclooxygenase 2 -
765 G>C polymorphisms in Alzheimer’s dementia. The Journal of the European College of 
Neuropsychopharmacology. Vol. 18, Suppl. 4, p. S203; IF2008: 3.661 (21st Congress of European 
College of Neuropsychopharmacology, Barcelona, Spain, 2008)  
A Juhász, Á Rimanóczy, Á Fehér, M Pákáski, J Kálmán, Z Janka. Association Analysis of BACE 
C786G and apolipoprotein E polymorphisms in Alzheimer’s disease. European Psychiatry. 2008; 
23: S195. (16th AEP Congress, Nice, France, 2008) 
Á Fehér, A Juhász, Á Rimanóczy, J Kálmán, Z Janka. BDNF Val66Met polimorfizmus vizsgálata 
demenciákban. [BDNF Val66Met polymorphism in dementias]. Neuropsychopharmacologia 
Hungarica, Volume X., Suppl 2, p. 18. (XI. Conference of Hungarian Neuropsychopharmacology, 
Tihany, Hungary, 2008) 
A Juhasz, Á Fehér, Á Rimanóczy, J Kálmán, Z Janka. Interferon gamma +874 T/A gene 
polymorphism is not a risk factor in the pathogenesis of Alzheimer’s disease. European 
Psychiatry. 2009; P01 95. (17th European Congress of Psychiatry, Lisbon, Portugal, 2009) 
Á Fehér, A Juhász, Á Rimanóczy, J Kálmán, Z Janka. Cytosolic phospholipase A2 BanI and 
cyclooxygenase-2 G-765C polymorphisms in Alzheimer’s disease. The Journal of the European 
College of Neuropsychopharmacology. Vol. 19, Suppl. 3, p. S238; IF2008: 3.661 (22nd Congress of 
European College of Neuropsychopharmacology, Istanbul, Turkey, 2009) 
Á Fehér, A Juhász, Á Rimanóczy, J Kálmán, Z Janka. Genetic interaction of alpha-7 nicotinic 
acetylcholine receptor and brain-derived neurotrophic factor polymorphisms in Alzheimer’s 
disease. Abstract book. p. 339. (10th World Congress of Biological Psychiatry, Paris, France, 
2009) 
Á Fehér, A Juhász, Á Rimanóczy, J Kálmán, Z Janka. Gyulladással kapcsolatos 
génpolimorfizmusok vizsgálata Alzheimer-kórban. [Neuronflammation-related gene 
polymorphisms in Alzheimer’s disease]. Volume XI., Suppl 3, p. 15-16. (XII. Conference of 
Hungarian Neuropsychopharmacology, Tihany, Hungary, 2009) 
Á Fehér, A Juhász, Á Rimanóczy, J Kálmán, Z Janka. Serotonin system gene polymorphisms in 
Alzheimer’s disease. European Psychiatry. European Psychiatry. 2010; PW67 (18th European 






5HT2A: serotonin receptor type 2A 
5HTT: serotonin transporter 
5HTTLPR: serotonin transporter gene-linked polymorphic region 
α7 nAChR: alpha-7 nicotinic acetylcholine receptor 
ACE: Addenbrooke’s Cognitive Examination 
AD: Alzheimer’s disease 
APOE: apolipoprotein E 
APP: amyloid precursor protein 
Aβ: amyloid-β 
BACE1: β-site APP cleaving enzyme-1 
BDNF: brain-derived neurotrophic factor 
CALHM1: calcium homeostasis modulator 1 
CHRFAM7A: fusion of the CHRNA7 exons 5-10 and FAM7A exons A-E 
CHRNA7: α7 nAChR subunit 
DHCR24: 24-dehydrocholesterol reductase 
FAM7A: family with sequence similarity 7A 
HWE: Hardy-Weinberg equilibrium  
IFNG: Interferon-γ 
MMSE: Mini-Mental State Exam 
NINCDS/ADRDA: National Institute of Neurological and Communicative Disorders and Stroke / 
Alzheimer’s Disease and Related Disorders Associations 
OR: odds ratio 
PCR: polymerase chain reaction 
PGE2: prostaglandin E2 
PLAG4A: cytosolic phospholipase A2, group IVA 
PSEN1: presenilin 1 
PSEN2:  presenilin 2 
PLAU: urokinase-type plasminogen activator 
PTGS2: prostaglandin endoperoxide synthase 2 
Seladin1: Selective AD Indicator 
SLC6A4: solute carrier family 6 member 4 gene encoding serotonin transporter 
SNP: single nucleotide polymorphism 
  
- 3 -
Table of contents 
 
Introduction ...................................................................................................................- 4 - 
I. Amyloid-β metabolism and AD...............................................................................- 7 - 
II. Cholesterol metabolism and AD ............................................................................- 9 - 
III. Neuroinflammation and AD .................................................................................- 9 - 
IV. Neuronal dysfunction and AD ............................................................................- 10 - 
Aims ............................................................................................................................- 13 - 
Subjects and Methods ..................................................................................................- 14 - 
Patients and controls.................................................................................................- 14 - 
Genetic analyses.......................................................................................................- 15 - 
Statistical analyses ...................................................................................................- 18 - 
Results .........................................................................................................................- 19 - 
I. Amyloid-β metabolism-related polymorphisms .....................................................- 20 - 
II. Cholesterol metabolism-related polymorphisms...................................................- 22 - 
III. Neuroinflammation-related polymorphisms........................................................- 24 - 
IV. Neuronal dysfunction .........................................................................................- 26 - 
Discussion....................................................................................................................- 31 - 
I. Amyloid-β metabolism-related polymorphisms .....................................................- 32 - 
II. Cholesterol metabolism-related polymorphisms...................................................- 33 - 
III. Neuroinflammation-related polymorphisms........................................................- 34 - 
IV. Neuronal dysfunction .........................................................................................- 35 - 
V. Genetic interactions .............................................................................................- 39 - 
Conclusions .................................................................................................................- 40 - 
Limitations...................................................................................................................- 41 - 
References ...................................................................................................................- 43 - 







Alzheimer’s disease (AD) is a progressive neurodegenerative disorder representing the most 
common cause of dementia in the elderly population (Ritchie and Lovestone, 2002). Current 
estimates indicate, that worldwide about 25-30 million people are suffering from AD, and the 
number of cases will triple by 2040 due to increasing life expectancy (Ferri et al., 2005). The 
incidence of AD increases with age: every five years after the age of 65 the risk of developing 
this devastating disease approximately doubles (Minati et al., 2009). In addition to the tragedy 
of the patients, AD places psychological and economical burden on caregivers, and represents 
a major public health problem being among the most costly diseases for the society in Europe 
and in the United States. 
 The clinical manifestation of AD is characterized by progressive memory impairment 
and cognitive deficits. Typically, AD begins with subtle and poorly recognized failure of 
memory that worsens inevitably. Further symptoms include confusion, impaired social 
judgment, language disturbance, agitation, withdrawal, irritability and impulsivity. AD 
pathology is characterized by the presence of extracellular senile plaques composed of 
amyloid-β (Aβ) peptid and intraneuronal neurofibrillary tangles containing 
hyperphosphorylated tau protein (Selkoe et al., 2001). The amyloid and the tau hypotheses 
consider these proteins as inducers and key players of the disease. Further neuropathological 
features include cortical atrophy, degeneration of cholinergic basal forebrain neurons, 
hippocampal atrophy and enlarged ventricles. 
 Genes have a varied influence on developing AD, ranging from the autosomal-
dominant inheritance in the familial forms (1-5% of cases) to the polygenic background in 
late-onset (>65 years of age) sporadic AD (≥95% of cases). In addition to the genetic 
component, the risk for developing AD, the age at onset and the course of the disease are 
influenced by several other factors including sociodemographic, life style, environment and 
comorbid medical conditions (Papassotiropoulos et al., 2006). Age and female sex represent 
risk for developing AD. Poor education, low mental ability, traumatic brain injury, stroke and 
history of depression can also predispose to AD. 
 The genetic component however, seems to be of major importance, since according to 




 The amyloid precursor protein (APP) and the presenilin 1 (PSEN1) and 2 (PSEN2) 
genes are currently known to be implicated in the familial forms of AD (Papassotiropoulos et 
al., 2006). Identification and characterization of dominant mutations of these genes was 
instrumental for the understanding of the biological mechanisms leading to enhanced Aβ 
accumulation and senile plaques generation. In contrast with the familial AD, the causing 
factors of the Aβ accumulations and other pathological mechanisms remain mostly unclear in 
the sporadic form. The complex genetic model of sporadic AD suggests that several 
heterogeneous susceptibility sets of genes may converge on the pathological processes that 
underlie the disease. However, so far only the apolipoprotein E (APOE) gene has been 
definitively associated with the risk for AD (Brouwers et al., 2008). 
 APOE is involved in lipid transport and metabolism. Furthermore, it plays a specific 
role in the central nervous system, including neuronal development, regeneration and certain 
neurodegenerative processes. The polymorphism of the APOE gene determines three isoforms 
of APOE protein (ε2, ε3, ε4) with different conformation and lipid binding properties 
(Cedazo-Mínguez and Cowburn, 2001). Proportional relationship was found between the 
number of the inherited ε4 alleles and the risk for developing AD and the age at onset. The 
APOE ε4 isoform prefers very low density lipoprotein and it is less effective in cholesterol 
transport as compared to the other APOE isoforms (Cedazo-Mínguez and Cowburn, 2001). 
Membrane cholesterol modulates the cleavage of the APP protein and in the presence of the 
ε4 isoform the balance is shifted to the production of Aβ (Stefani and Liguri, 2009). 
 The amyloid cascade hypothesis has been the predominant model of molecular 
mechanisms underlying the pathogenesis of AD. According to this model, the fundamental 
cause of AD is the accumulation and aggregation of the Aβ peptide in the brain (Hardy and 
Selkoe, 2002). The amyloid cascade hypothesis is widely accepted, but does not explain all 
aspects of AD aetiology, and the major role of other pathogenic mechanisms is also 
presumable including inflammation, oxidative stress, lipid dysfunction, signaling deficits and 
neuronal dysfunction. 
 The genetic epidemiology of sporadic AD remains a very active area of research, since 
a large part of the genetic aetiology is still poorly understood and remains unresolved. The 
aim of our work was to contribute to this field investigating gene polymorphisms presumably 
involved in AD pathogenesis. The candidate gene polymorphisms in this study were selected 
and grouped on the basis of the processes that presumably lead to the development of AD: Aβ 
metabolism, cholesterol metabolism, neuroinflammation and neuronal dysfunction (Figure 1). 
The characteristics of the investigated gene polymorphisms are summarized in Table 1. 
Table 1. Investigated polymorphisms  
 
Gene The investigated polymorphisms 
Official symbol Name 
Chromosomal 
localization Rs number Position 
Changes at 
protein level 
Alleles Functional consequences 
APOE apolipoprotein E 19q13.2 rs429358 
rs7412 
exon 4 C/T 
exon 4 C/T 
Cys112Arg 
Cys158Arg 
ε2, ε3, ε4 ε4 allele: ↓ cholesterol transport 
BACE1 
 
beta-site APP-cleaving enzyme 1 11q23.3 rs638405 exon 5 C/G  - (Val262) 
Silent mutation 
C, G Not known 
PLAU 
 
plasminogen activator, urokinase 10q22.2 rs2227564 exon 6 C/T Pro141Leu C, T Not known 
CALHM1 
 
calcium homeostasis modulator 1 10q24.33 rs2986017 exon 1 T/C Leu86Pro  Leu, Pro Leu allele: ↓ CALHM1 function 
DHCR24 
 
24-dehydrocholesterol reductase 1p33-p31.1 rs600491 intron 5 C/T - C, T Not known 
DHCR24 
 
24-dehydrocholesterol reductase 1p33-p31.1 rs638944 intron 2 G/T - G, T Not known 
IFNG 
 
interferon, gamma 12q14 rs2430561 intron 1 T/A - T, A T allele: ↑ IFNG level 
PLA2G4A  phospholipase A2, group IVA 
(cytosolic, calcium-dependent) 
1q25 rs10798059 intron 1 A/G - A1, A2 A2 allele: ↑ PLA2G4A level 
PTGS2 prostaglandin-endoperoxide synthase 2 
(cyclooxygenase 2) 
1q25.2-q25.3 rs20417 promoter G/C - G, C G allele: ↑ PTGS2 promoter activity 
CHRFAM7A CHRNA7 (cholinergic receptor, 
nicotinic, alpha 7, exons 5-10) and 
FAM7A (family with sequence 
similarity 7A, exons A-E) fusion 
15q13.1 - exon 6 deletion, frameshift -2bp, wild -2bp allele: stop codon 
SLC6A4 
(5HTTLPR) 
solute carrier family 6, member 4 
(serotonin transporter gene-linked 
polymorphic region) 
17q11.1-q12 rs4795541 promoter insertion/deletion L, S  S allele: ↓ serotonin reuptake 
HTR2A 5-hydroxytryptamine (serotonin) 
receptor 2A 
13q14-q21 rs6313 exon 1 T/C - (Ser34) 
Silent mutation 
T, C C: ↓ HTR2A gene activity 
BDNF 
 






Figure 1. The pathological cascade of Alzheimer’s disease (AD) 
 
Mutations of the amyloid precursor protein (APP) and the presenilin genes (PS) cause familial forms of AD by 
increasing the accumulation of amyloid-β (Aβ). In the sporadic form of AD multiple environmental and genetic 
risk factors interact through various pathways to cause neurodegeneration. Aging is a major contributor, and the 
apolipoprotein E (APOE) gene is so far the only unequivocally confirmed genetic risk factor for sporadic AD. 
The investigated genes (shown with red) of this study were selected and grouped on the basis of the main 
pathological processes presumably leading to AD. 
 
I. Amyloid-β metabolism and AD 
 
APP is a single transmembrane polypeptide with characteristics of a cell surface receptor. The 
primary function of APP is unknown, but it is believed to have role during neuronal 
development, to be implicated in synaptic formation and repair, signaling and cell adhesion 
(Walsh et al., 2007). APP follows two distinct cleavage pathways competing α- and β-
secretases, and both pathways are active in normal metabolism (Selkoe et al., 2001). The 
predominant cleavage of APP is mediated by the α-secretase generating non-amyloidogenic 
products. The cleavage leading to Aβ generation is mediated by β- and γ-secretases. PSEN1 
and PSEN2 are part of the γ-secretase complex. 
 The β-site APP cleaving enzyme-1 (BACE1) gene at locus 11q23.3 encodes β-
secretase, the key and rate-limiting enzyme in the cascade of Aβ formation. Genetic variations 
of BACE1 may act on the Aβ generation and thereby influence neurodegenerative processes 
leading to AD. The rs638405 synonymous polymorphism of BACE1 is a nucleotide change in 
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exon 5 (C786G) with no alteration at the amino acid level (Val262) (Murphy et al., 2001). 
The reports of the association studies on the role of BACE1 in AD are contradictory. Some 
studies have reported that the BACE1 C786G polymorphism influences the risk for AD, 
especially in those carrying the APOE ε4 allele (Clarimon et al., 2003, Kirschlint et al., 2003; 
Cai et al., 2005). However, other authors have not found such an association (Murphy et al., 
2001; Jo et al., 2008; Todd et al., 2008). This study is the first report on BACE1 C786G 
polymorphism in the Hungarian population. 
 The PLAU gene encoding urokinase-type plasminogen activator (uPA) maps to 
chromosome 10q22.2, a candidate susceptibility locus in a broad AD linkage region (10q21-
24) (Riemenschneider et al., 2006). The uPA serine protease converts the inactive 
plasminogen to the active plasmin form, and it is also capable to degrade Aβ directly. Plasmin 
promotes α-cleavage of APP, degrades secreted and aggregated Aβ, thereby blocks Aβ 
neurotoxicity (Finckh et al., 2003). The frequent single nucleotide polymorphism (SNP) of 
PLAU (rs2227564, C1788T) is located in exon 6, and results in an amino acid change at 
codon 141 (Pro141Leu). The findings of the association studies investigating the Pro141Leu 
polymorphism in AD are controversial, therefore further evaluations of genotypic distribution 
are required (Finckh et al., 2003; Myers et al., 2004; Ertekin-Taner et al., 2005; Bagnoli et al., 
2005; Papassotiropoulos et al., 2005; Riemenschneider et al., 2006). 
 An increasing body of evidence supports the major contribution of the dysregulation 
of calcium homeostasis in accelerating pathological changes in AD, i.e. Aβ accumulation 
(Bezprozvanny and Mattson, 2008). A promising candidate gene for AD, the calcium 
homeostasis modulator 1 (CALHM1) has been recently identified at position 10q24.33, in the 
same AD linkage region (10q21-24), where the PLAU gene is also located. It is localized both 
in the cell and in the endoplasmatic reticulum membranes and it appears to modulate the 
intracellular calcium levels (Dreses-Werringloer et al., 2008). 
 An SNP (rs2986017) at nucleotide 257 (C/T) producing a non-conservative amino 
acid substitution at codon 86 (Pro86Leu) has been identified. The Leu allele has been reported 
to be associated with AD, and in vitro demonstrated to result in impaired CALHM1 function 
leading to decreased calcium permeability and reduced cytoplasmic calcium levels (Dreses-
Werringloer et al., 2008). Intracellular calcium levels were reported to affect the metabolism 
of APP and thereby the levels of Aβ (Green et al., 2008; Tanzi et al., 2008). With regards to 
the hypothesis that CALHM1 polymorphism may represent a susceptibility factor for AD, 
recent association studies failed to support this possibility (Bertram et al., 2008; Minster et al., 
2009, Sleegers et al., 2009). 
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II. Cholesterol metabolism and AD 
 
Cholesterol is a necessary structural component and cell fluidity modulator of the cell 
membrane. Most of the CNS cholesterol is produced via local de novo synthesis. The role of 
cholesterol in AD is a controversial topic, but it seems that an optimal amount of cell 
cholesterol may be critical for brain homeostasis (Peri and Serio, 2008). The amount of cell 
cholesterol has a major impact on Aβ generation and cell resistance against Aβ toxicity. 
 The 24-dehydrocholesterol reductase (DHCR24) gene at locus 1p33-p31.1 encodes 
Seladin1 (Selective AD Indicator), an enzyme that is involved is cholesterol biosynthetic 
pathway. Seladin1 catalyses the conversion of desmosterol to cholesterol, but also has other 
relevant biological effects. Seladin1 confers resistance against Aβ and oxidative stress 
induced apoptosis by effective inhibition of caspase-3 activity, and prevention of p53 
degradation (Peri and Serio, 2008). Seladin1 also affects the Aβ generation via the modulation 
of membrane cholesterol content. 
 The genetic association between Seladin1 and risk for AD was investigated by Lämsä 
and co-workers genotyping four SNPs of DHCR24 genes: rs638944 (intron 2 G/T), rs600491 
(intron 5 C/T), rs718265 (intron 6 A/G), rs7374 (exon 9 C/T) (Lämsä et al., 2007). No 
significant association of single SNPs with AD risk was found, but in men the T allele of 
rs600491 increased the risk for AD. Haplotype analyses revealed, that from the two haplotype 
blocks (block 1: rs638944 and rs600491; block 2: rs718265 and rs7374), only block 1 showed 
significant association with risk for AD, being CG the risk haplotype (Lämsä et al., 2007). 
 
III. Neuroinflammation and AD 
 
An increasing body of evidence supports the major contribution of inflammatory processes in 
accelerating pathological changes in AD (Lukiw and Bazan, 2000). The activated microglia-
driven inflammatory response resulted in an elevated release of various pro-inflammatory 
mediators such as cytokines and prostaglandins which may interact at multiple levels with 
neurodegeneration (Heneka and O’Banion, 2007). The extent of the inflammatory response 
can be influenced by the individual’s genetic background of inflammatory mediators (Wan et 
al., 2008). The cytokine interferon-γ (IFNG) plays an important role in the induction of the 
immune-mediated inflammatory response (Blasko, 2001). In human neuroblastoma cells pre-
treatment with IFNG increased the expression of cytosolic phospholipase A2, group IVA 
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(PLAG4A) resulting in an elevated release of arachidonic acid and a subsequently elevated 
level of prostaglandins (Bate et al., 2006). The T allele of the IFNG T874A polymorphism 
correlates with an increased level of IFNG (Pravica et al., 2000). Association studies did not 
support the hypothesis that the IFN-γ T874A polymorphism may represent a risk factor for 
AD (Scola et al., 2003; Galimberti et al., 2004). Phospholipase A2 is a superfamily of 
enzymes that include key modulators of cerebral phospholipid metabolism. The PLA2G4A 
catalyzes the release of arachidonic acid from membrane phospholipids. A polymorphic site 
for BanI restriction enzyme in PLA2G4A gene is an A to G base change (Wei and Hemmings, 
2004). According to our knowledge this is the first report on PLA2G4A BanI polymorphism 
in AD. 
 Prostaglandin endoperoxide synthase 2 (PTGS2) is a key enzyme in prostaglandin 
biosynthesis converting arachidonic acid to prostaglandin E2 (PGE2). A functional 
polymorphism (G-765C) in the promoter region of the PTGS2 gene has been identified and 
significantly lower promoter activity has been reported for the C allele (Papafili et al., 2002). 
Abdullah and co-workers reported that the possession of the C allele is associated with 
decreased risk for AD (Abdullah et al., 2006). PLA2G4A and PTGS2 are involved in the 
same pathway of prostaglandin synthesis and both PLA2G4A and PTGS2 genes are located at 
the same 1q25 region, thus these two genes may interact in many ways. Since IFNG has been 
demonstrated to elevate PLA2G4A expression, it may also interplay in the generation of 
prostaglandins therefore a combined effect with PLA2G4A and PTGS2 can be postulated. 
Besides its major role in cholesterol metabolism and its involvement in Aβ generation, 
APOE plays also an isoform-specific role in mediating brain inflammatory response. Cell 
culture studies reported association between the presence of APOE ε4 and increased 
inflammatory response (Jofre-Monseny, 2007). Mouse macrophages transfected with APOE 
ε4 secrete significantly more pro-inflammatory cytokines as compared to those transfected 
with APOE ε3 (Tsoi, 2007). 
 
IV. Neuronal dysfunction and AD 
IV.1. Cholinergic dysfunction 
 
AD is associated with a progressive loss of cholinergic neurons and a consequent 
acetylcholine deficit, particularly in the temporal and parietal neocortex and hippocampus. 
The extensive degeneration of the cholinergic neurons in the basal nucleus of Meynert and in 
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the medial septal nucleus is responsible for the loss of up to 95% of the cholinergic 
innervation to the cortex. The reduced activity of choline acetyltransferase also contributes to 
the decreasing availability of acetylcholine. It is also presumable that altered activity of 
acetylcholine receptors determined by genetic variations can also influence the cholinergic 
transmission. 
 Alpha-7 nicotinic acetylcholine receptors (α7 nAChRs) are homopentamer, ligand-
gated cationic channels. They are widely expressed in the central nervous system with high 
levels in the regions relevant to memory functions and involved in processing of sensory 
information, such as hippocampus (Weiland et al., 2000). It has been demonstrated that Aβ 
binds to α7 nAChR with high affinity and they both are present in senile plaques (Wang et al., 
2000). Their interaction alters several neurochemical processes including Ca2+ homeostasis 
and acetylcholine release, and thereby modulates neuronal physiological functions implicated 
in memory processes. Chronic inhibition of cholinergic signaling by Aβ could contribute to 
the cognitive deficits associated with AD (Pettit et al., 2001). 
 The α7 nAChR subunit gene (CHRNA7) at region 15q13.1 is duplicated from exon 5 
to 10 (Gault et al., 1998; Riley et al., 2002). The partially duplicated CHRNA7 and four other 
exons originated from Family with sequence similarity 7A (FAM7A) gene form a hybrid gene 
(CHRFAM7A). CHRFAM7A is not present on every human chromosome and some 
individuals lack one (30%) or both (5%) copies (Riley et al., 2002). A -2bp deletion 
polymorphism at position 497-498 in exon 6 was identified, which is specific to CHRFAM7A 
and does not occur in CHRNA7 (Gault et al., 1998). The -2bp deletion causes a frameshift, 
introducing a stop codon within exon 6 and therefore a truncation in a putative gene product. 
Since CHRFAM7A is reported to be expressed as mRNA, possible regulatory effects should 
also be considered. Liou and co-workers (2001) failed to find association between 
CHRFAM7A -2bp deletion polymorphism and AD, investigating a relatively low number of 
cases in an Asian population (Liou et al., 2001). 
 
IV.2. Serotonergic dysfunction 
 
History of depression, and in particular with first onset before 60 years of age, represents risk 
for developing AD later in life (Geerlings et al., 2008). Possible links between AD and 
depression may be the long term occurrence of inflammatory processes, and the involvement 
of serotonergic disturbances (Ownby et al., 2006). Serotonergic involvement in AD is 
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supported by findings including cerebrospinal fluid alteration of serotonin (5HT) and loss of 
synthesizing neurons and 5HT receptors in AD. 
 The solute carrier family 6 member 4 (SLC6A4) gene at locus 17q11.1-q12 encodes 
5HT transporter (5HTT). The promoter region of the SLC6A4 gene shows a 22 bp tandem 
repeat polymorphism, which is designated as 5HTT gene-linked polymorphic region 
(5HTTLPR). The two major alleles have 14 and 16 repeats, thus differing in 44 bp, and were 
denoted as short (S) and long (L) alleles. The 5HTTLPR polymorphism determines dose-
dependent 5HT reuptake from the synaptic cleft, the S allele is less effective. Association 
studies reported mainly negative results investigating the relationship between AD and 
5HTTLPR (Seripa et al., 2008; Micheli et al., 2006; Grünblatt et al., 2008). 
 The gene HTR2A, which codes for the 5HT receptor type 2A (5HT2A) is located at 
13q14–q21. The rs6313 polymorphism of HTR2A is a nucleotide change in exon 1 (T102C), 
and does not alter the serine at position 34 (silent mutation). This polymorphism is located 
near to the promoter region thereby may have some role in the regulation of gene expression. 
The activity of the C allele has been shown to be significantly decreased as compared to the T 
allele. Association studies did not support the association of HTR2A T102C and 5HTTLPR 
polymorphisms with AD, when they were separately analyzed (Micheli et al., 2006; Lam et 
al., 2004). However, Micheli and co-workers (2006) found an interaction between the HTR2A 
T102C and 5HTTLPR polymorphisms: HTR2A C/C and 5HTTLPR L/L genotype carriers 
had an increased risk for AD. 
 
IV.3. Brain-derived neurotrophic factor 
 
The brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of 
growth factors, produced by cortical neurons. Besides its general role in neurodevelopment, 
BDNF has important functions in the adult brain such as promoting the survival and 
maintaining the structural integrity of neuronal cells (Murer et al., 2001). The activity-
dependent expression of BDNF plays a role in modulating synaptic changes associated with 
learning and memory (Tyler et al., 2002). It has been reported that patients with AD have 
reduced BDNF levels in the hippocampus and in the temporal cortex as compared to healthy 
controls (Ferrer et al., 1999).  
 The BDNF gene encodes a precursor peptide (pro-BDNF) which is secreted and 
cleaved by extracellular protease to form the mature BDNF protein (Seidah et al. 1996). An 
SNP at nucleotide 196 (G/A) producing a non-conservative amino acid substitution at codon 
  
- 13 -
66 (Val/Met) has been identified (Ventriglia et al., 2002). Although this SNP is located in the 
5’ pro-BDNF sequence and does not affect the function of the mature BDNF, it has a major 
impact on the intracellular trafficking and regulated secretion of pro-BDNF (Egan et al., 
2003). Genetic influences on BDNF secretion can lead to alterations in hippocampal activity. 
The BDNF Val66Met polymorphism has been found to be associated with episodic memory 
and hippocampal function (Hariri et al., 2003). Nevertheless, there are conflicting reports on 
the correlation between AD and BDNF Val66Met polymorphism (Combarros et al., 2004; 





 The aim of our investigation was to provide data on APOE polymorphism in the 
Hungarian population to further confirm the role of ε4 allele in AD. 
 We tested the hypothesis whether the BACE1 C786G and PLAU Pro141Leu 
polymorphisms are associated with AD, either alone or in genetic interaction. 
 With reference to the Dreses-Werringloer paper (2008) we tried to support their 
findings, that CALHM1 Leu86 allele can increase the risk for developing AD. 
 The aim of our study was to test the hypothesis that the rs638944 and rs600491 
polymorphisms of the DHCR24 gene encoding Seladin1 influence the 
susceptibility to AD. 
 We investigated the possible role of IFNG T874A, PLA2G4A BanI and PTGS2 
G-765C polymorphisms in AD. Our study was undertaken to confirm the 
hypothesis that the above-mentioned variants of these genes, either alone or in 
epistasis, may represent a risk factor for AD. 
 The aim of our study was to test the hypothesis that the CHRFAM7A -2bp 
deletion polymorphism confers predisposition to AD. 
 We investigated the possible role of HTR2A T102C and 5HTTLPR 
polymorphisms in AD either alone or in genetic interaction. 
 We tested the hypothesis that the BDNF Val66Met polymorphism influences the 
risk for developing AD. 
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Subjects and Methods 
 
Patients and controls 
 
A total of 495 Hungarian Caucasian subjects were enrolled in this study. The characteristics 
of the participants are presented in Table 2. The study included 250 patients with late onset 
AD recruited from the Memory Clinic of the Department of Psychiatry, University of Szeged. 
The diagnosis of probable AD fulfilled the criteria for Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition (DMS-IV) and National Institute of Neurological and 
Communicative Disorders and Stroke / Alzheimer’s Disease and Related Disorders 
Associations (NINCDS/ADRDA) (McKhann et al., 1984). All AD cases were defined as 
sporadic since in their family history there was no first or second degree relative with 
dementia. 
 






Age (years; mean ± SD) 76.8 ± 7.3 75.2 ± 6.9 
Age at onset (years; mean ± SD) 72.4 ± 6.1 - 
Male/female (%) 32/68 31/69 
MMSE (scores; mean ± SD) 18.5 ± 5.9 29.1 ± 0.9 
ACE (scores; mean ± SD) 53.5 ± 13.4 - 
APOE ε4 allele carrier (%) 46.4 13.8 
AD: Alzheimer’s disease; HC: healthy control; MMSE: Mini-Mental State Exam; 
ACE: Addenbrooke’s Cognitive Examination; APOE ε4 allele carrier: 
apolipoprotein E ε4 allele carrier (homozygous or heterozygous) 
 
 
 The clinical diagnosis of probable AD was supported by psychiatric and neurological 
examinations, basic clinical tests such as Mini-Mental State Exam (MMSE), Addenbrooke’s 
Cognitive Examination (ACE) including Clock Drawing and Verbal Fluency tests. The AD 
patients all had experienced a progressive loss of cognitive functions (in more than two 
cognitive domains indicative of cortical dysfunction) for at least 1 year with memory loss as 
the most significant symptom. Brain CT or MRI images were also evaluated. 
 As a healthy control (HC) group we studied 245 elderly, cognitively intact, healthy 
individuals that were selected from visitors of patients at the Memory Clinic, Department of 
Psychiatry, University of Szeged. All of them were medication free and lack of any 
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significant illnesses and any signs of dementia. Informed consent was obtained from the 
subjects participated in this study and all protocols were approved by the local ethics 
committee. 
 MMSE was used as a measure of global cognitive performance. MMSE scores in the 
HC group were higher than 28 points (mean ± SD: 29.1 ± 0.9) and none of the probands had 
any verified symptoms of dementia. The mean MMSE score in the AD group was 18.5 ± 5.9 




Blood samples were taken by venous puncture. Genomic DNA was extracted from peripheral 
blood leukocytes according to a standard procedure using the Roche kit. The genetic analyses 
were performed by polymerase chain reaction (PCR) based methods or direct sequencing. 
PCR products and digested fragments were separated by agarose or polyacrilamide gel 
electrophoresis with ethidium bromide staining. Bands on gels were detected and documented 
by Quantity One 1-D Analysis software of BioRad GelDoc System. 
 APOE genotypes were determined by a previously described PCR-restriction fragment 
length polymorphism (RFLP) method with the restriction enzyme CfoI (Kálmán et al., 1997). 
Genotyping of the BACE1 polymorphism was done by PCR amplification and enzymatic 
digestion with restriction enzyme BclI (Cai et al., 2005). Genotyping of the PLAU 
polymorphism was assessed by restriction enzyme AluI with the same method described by 
Pesaresi et al (Pesaresi et al., 2006). 
 The DNA samples were genotyped for CALHM1 polymorphism through direct 
sequencing of a 291 bp long PCR product. The primers used in the amplification were: 
forward primer 5’-TCC TTC ATG AAT GGC ATC TG-3’ and reverse primer 5’-CCC AGA 
CGA CAG GCG CGA TG-3’. The following 25 µl reaction mixture was used for the PCR 
amplification: 50 ng of genomic DNA, 10 pmol of each primer (Invitrogen), 1.5 mM MgCl2, 
200 µM dNTP mix, 1 unit Taq polymerase (BioRad).  
 The amplification program consisted of an initial denaturation step of 3 min at 95°C, 
then 5 cycles with three temperature segments: 30 sec at 95°C for denaturation; 30 sec at 
70°C for annealing; 30 sec at 72°C for amplification. The next step was 25 cycles of three 
temperature segments: 30 sec at 95°C for denaturation; 30 sec at 61°C for annealing; 30 sec at 
72°C for amplification. At last 72°C for 2 min was performed.  
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 The PCR products were purified by ethanol precipitation and bidirectionally 
sequenced. Direct sequencing of the PCR products was performed using the BigDye 
Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems) on the ABI 3100 
Genetic Analyzer (Applied Biosystems). Obtained sequences were analyzed using Applied 
Biosystem Sequencing Analysis v.3.7 software. 
 The primers used in the genotyping of the DHCR24 rs600491 polymorphism were: 
forward primer 5’-CCT CCT CAG CTT TCC TAC CC-3’ and reverse primer 5’- TCC AGC 
TTC TGA CTC CTG GT-3’. The following 25 µl reaction mixture was used for the PCR 
amplification: 50 ng of genomic DNA, 10 pmol of each primer (Invitrogen), 1.5 mM MgCl2, 
200 µM dNTP mix, 1 unit Taq polymerase (BioRad).  
 The amplification program consisted of an initial denaturation step of  5 min at 94°C, 
then 25 cycles of three temperature segments: 30 sec at 94°C for denaturation; 30 sec at 66°C 
for annealing; 30 sec at 72°C for amplification. At last 72°C for 5 min was performed. After 
amplification, the PCR products were digested with (1 unit/5µl of PCR product) AciI 
restriction enzyme at 37 ºC for 12 hours. 
 The PCR product was a 309 bp DNA fragment, which has one cleaving site for AciI in 
case of the T allele and two cleaving sites in case of the C allele. The digested fragments of 
the T allele were 214 and 95 bp of length. The C allele resulted in 187, 27 and 95 bp 
fragments. 
 The DHCR24 rs638944 polymorphism was determined by allele specific primers in 
two parallel PCR reactions. To asses the success of the PCR amplification a generic control 
PCR product of 667 bp was amplified in each reaction using the following primers: forward 
primer 5’- CTG CTG CAC ACA GAA GGT GT -3’ and reverse primer 5’- TTT GCG GTT 
CAC AGT ACC AA -3’.  
 The allele specific primers used in the genotyping of the DHCR24 rs638944 
polymorphism were: T allele specific forward primer 5’- TTC TGG CTC TCG GTT AGC 
TAG T -3’ and G allele specific forward primer 5’- CTG GCT CTC GGT TAG CTA GG -3’. 
The common reverse primer for the allele specific primers was the same as the one for the 
control forward primer. The allele specific PCR product for the DHCR24 rs638944 
polymorphism was 552 bp long. 
 One of the two parallel multiplex PCR reactions contained the DHCR24 rs638944 G 
allele specific primer with the suitable reverse primer and the generic control primers. The 
other reaction contained the DHCR24 rs638944 T allele specific primer with the suitable 
reverse primers and the generic control primers. 
  
- 17 -
 The following 25 µl reaction mixture was used for the PCR amplification: 50 ng of 
genomic DNA, 10 pmol of each primer (Invitrogen), 1.5 mM MgCl2, 200 µM dNTP mix, 1 
unit Taq polymerase (BioRad). The amplification program consisted of an initial denaturation 
step of  30 sec at 95°C followed by 25 cycles of three temperature segments: 30 sec at 95°C 
for denaturation; 30 sec at 65°C for annealing; 30 sec at 72°C for amplification. At last 72°C 
for 3 min was performed.  
 Genotyping of the IFNG polymorphism was done by PCR amplification with allele 
specific primers as described by Raitala and co-workers (Raitala et al., 2005). Genotyping at 
PLA2G4A loci was assessed by restriction enzyme BanI with the same method described by 
Chowdari et al (Chowdari et al., 2004). The two alleles of the PLA2G4A BanI polymorphism 
are designated as A1 (with nucleotide A) and A2 (with nucleotide G, the BanI-cut allele). 
Genotyping of the PTGS2 polymorphism was done by PCR amplification and enzymatic 
digestion with restriction enzyme AciI (Papafili et al., 2002). 
 Genotyping of the CHRFAM7A -2bp deletion polymorphism was done by PCR 
amplifications, and the two bp difference between the wild and the -2bp deletion alleles was 
revealed by 10% polyacrilamide gel electrophoresis with ethidium bromide staining (Lai et 
al., 2001). We were focusing on the deletion polymorphism of the CHRFAM7A, and did not 
investigate the copy number, therefore we determined three groups. The genotype lacking the 
-2bp deletion was designated genotype 1, genotype having one copy of the -2bp allele was 
designated genotype 2 and genotype with two copies of the -2bp allele was designated 
genotype 3. 
 Genotyping of the 5HTTLPR polymorphism was carried out as previously described 
(Sundaramurthy et al., 2000). The 44 bp difference between the 5HTTLPR L and the S alleles 
was revealed by 2% agarose gel electrophoresis with ethidium bromide staining. The HTR2A 
primers used in the amplification were described by Virgos et al (2001). After amplification, 
the PCR products were digested with MspI restriction enzyme at 37 ºC for 12 hours. 
 Genotyping of the BDNF Val66Met polymorphism was done by PCR amplification 









The program SPSS 15.0 was used for all statistical analyses, and the significance level was set 
at p<0.05. Fisher’s exact and Pearson’s χ2 tests were used to compare gender, Hardy-
Weinberg equilibrium (HWE), allele and genotype frequencies between the AD and HC 
groups. The mean age of the AD and HC groups was compared by using the t-test for 
independent samples. Analysis of variance was carried out to determine possible effect of the 
different genotypes on age at onset of AD. A logistic regression model was applied to test for 
interactions between the investigated polymorphisms and to estimate crude and adjusted odds 
ratios (ORs) with 95% confidence intervals (95% CI) in testing for possible associations 






Statistically no significant difference in mean age or in the distribution of genders between 
AD and HC groups was found (p>0.05). A deviation from the HWE was detected in IFNG 
genotype distribution in the HC population (p=0.002), and in PLA2G4A genotype distribution 
in the AD group (p=0.008). All the other investigated genotype frequencies were in HWE for 
cases and controls, respectively (p>0.05). 
 As expected from many previous studies the genotypes with the APOE ε4 allele were 
significantly over-represented in the AD group as compared to the controls (p<0.0001). 
APOE genotype frequencies observed in the investigated groups are shown in Table 3. 
Among the patients with AD, no APOE ε2/ε2 carriers were detected and even in the HC 
group only four cases were found. The heterozygous ε2/ε3 genotype also occurred with low 
frequency in AD (AD: 4.8%, versus HC: 11.0%). The ratio of the ε3/ε4 carriers was 
significantly higher in AD than in HC group (AD: 34.4%, HC: 12.2%). The occurrence of the 
ε4 allele were significantly over-represented in AD as compared to HC (AD: 27.8%, HC: 
7.1%, p<0.0001). 
 The crude ORs for AD conferred by APOE genotypes are presented in Figure 2. The 
following genotype categories were designated: 1=ε2/ε2 and ε2/ε3; 2=ε3/ε3; 3=ε2/ε4 and 
ε3/ε4; 4=ε4/ε4, considering ε3/ε3 genotype as the reference. The OR for AD was reduced in 
ε4 negative carriers of ε2 allele, and was higher in the ε4 positive individuals as compared to 
those with ε3/ε3 genotype. The ε4 homozygotes have significantly increased risk for AD 
(OR=4.29), than ε4 heterozygotes (OR=16.97), which further supports the previous results of 
the allele dose dependent risk of APOE ε4 allele for AD. 
 Stratification according to gender revealed an increased risk for AD in women 
carrying the ε4/ε4 genotype (OR=22.29; p=0.003) as compared to men with the ε4/ε4 
genotype (OR=11.61; p=0.024). However, the same effect size was calculated for women 
(OR=4.05; p<0.001) and men (OR=4.81; p<0.001) carrying the ε3/ε4 genotype. In case of ε4 
negative carriers of ε2 allele the OR for AD was reduced - but not significantly - both in 
women and in men as compared to the ε3/ε3 carriers. No statistically significant differences 
were found between the means of the age at onset among the AD patients with the different 












ε2/ε2 0 (0%) 4 (1.6%) 
ε2/ε3 12 (4.8%) 27 (11.0%) 
ε2/ε4 7 (2.8%) 3 (1.2%) 
ε3/ε3 122 (48.8%) 180 (73.5%) 
ε3/ε4 86 (34.4%) 29 (11.8%) 
ε4/ε4 23 (9.2%) 2 (0.8%) 
* χ2=68.357 (5), p<0.0001 















Figure 2. Odds ratios (ORs) with 95% CI for AD conferred by APOE genotypes 
The genotypes are ranked by the increasing risk for AD, considering ε3/ε3 
genotype as reference category (OR=1). Genotypes: 1=ε2/ε2, ε2/ε3; 2=ε3/ε3; 
3=ε2/ε4, ε3/ε4; 4=ε4/ε4. 
 
I. Amyloid-β metabolism-related polymorphisms 
 
The BACE1 and PLAU genotype frequencies observed in the examined groups are presented 
in Table 4. Comparison of BACE1 genotype frequencies between AD and HC groups did not 
reach statistically significant difference (p=0.647). The percentage of the different PLAU 
genotypes was similar in AD as compared to HC, and showed no statistically significant 
difference (p=0.964). Logistic regression analysis revealed no effect of interaction between 
PLAU and BACE1 genotypes (p=0.716), and there was also no interaction with APOE ε4 
allele on AD risk (BACE1*APOE: p=0.648; PLAU*APOE: p=0.579). 
 As presented in Table 5, the CALHM1 Pro/Leu and Leu/Leu genotypes occurred with 
higher frequency in AD as compared to HC group, although the difference did not show 
statistical significance (p=0.153). Given the relatively low occurrence of the Leu/Leu 
genotype both in AD cases and in controls, the analysis was also conducted by presence or 
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absence of the Leu allele in the genotypes. The frequency of the Leu+ genotypes (Leu/Leu 
and Pro/Leu genotypes together) was found to be marginally significantly higher in the AD 
than in the HC group (AD: 53.8%, HC: 44.6%; p=0.056). The crude ORs for AD conferred by 
CALHM1 genotypes are presented in Figure 3. The effects of Pro/Leu or Leu/Leu genotypes 
on AD risk were not significant. The Leu+ genotypes had a marginally significantly increased 
risk for AD (OR=1.45; p=0.053) considering Pro/Pro genotype as reference category (OR=1). 
 






BACE1 *   
CC 50 (20.9%) 35 (17.4%) 
CG 117 (49.0%) 102 (50.7%) 
GG 72 (30.1%) 64 (31.9%) 
PLAU #   
CC 156 (65.4%) 129 (64.1%) 
CT 78 (32.6%) 68 (33.8%) 
TT 4 (2.0%) 4 (2.1%) 
* χ2=0.870 (2), p=0.647 
# χ2=0.073 (2), p=0.964 
BACE1: β-site APP cleaving enzyme-1; PLAU: urokinase-type plasminogen 
activator; AD: Alzheimer’s disease; HC: Healthy control 
 
 








Pro/Pro 110 (46.2%) 112 (55.4%) 
Pro/Leu 101 (42.5%) 70 (34.7%) 
Leu/Leu 27 (11.3%) 20 (9.9%) 
χ2=3.760 (2) p=0.153 
CALHM1: Calcium homeostasis modulator1; AD: Alzheimer’s disease; 















Figure 3. Odds ratios (ORs) with 95% CI for AD conferred by CALHM1 genotypes 
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 According to the frequency data, the possession of the CALHM1 Leu and the APOE 
ε4 alleles was considered as possible risk factors for AD. Table 6 summarizes the frequencies 
and ORs for the interaction between the probable risk factors for AD. Both AD and HC 
groups were divided into subgroups according to the presence or absence of CALHM1 Leu 
and APOE ε4 alleles. The OR for the co-presence of CALHM1 Leu and APOE ε4 alleles was 
higher (OR=6.69; p<0.0001) than the ORs for the possession of only one of them (ε4 allele: 
OR=4.28, p<0.0001; Leu allele: OR=1.49, p=0.093). The effect of the Leu allele without the 
ε4 allele is not significant. The interaction between the CALHM1 Leu and APOE ε4 alleles 
did not contribute significantly to the logistic regression model (p=0.913). 
 










OR 95% CI p* 
 
+ + 58 (24.4%) 14 (6.9%) 6.687 3.419–13.076 <0.0001 
+ - 53 (22.3%) 20 (9.9%) 4.277 2.321–7.882 <0.0001 
- + 70 (29.4%) 76 (37.6%) 1.487 0.935–2.362 0.093 
- - 57 (23.9%) 92 (45.6%) reference 
The reference category is HC.  * Result of Wald statistics. 
APOE ε4: Apolipoprotein E ε4 allele; CALHM1 Leu: Calcium homeostasis modulator1 Leu allele;  
AD: Alzheimer’s disease; HC: Healthy control 
 
 
 Analyzing the results according to gender and age at onset, no interactions among 
these factors and the investigated polymorphisms (BACE1, PLAU, CALHM1) were observed 
(p>0.1). Given the co-localization of PLAU and CALHM1 genes in the 10q21-24 AD linkage 
region, a possible interaction between PLAU and CALHM1 on prediction of AD was 
assessed, but no interaction was found (p=0.891). 
 
II. Cholesterol metabolism-related polymorphisms 
 
The DHCR24 rs600491 genotype frequencies observed in the investigated groups are shown 
in Table 7. The DHCR24 rs600491 genotype and allele distributions did not differ 
significantly between the AD and HC groups (p=0.881 for genotypes; p=0.845 for alleles). 
Stratification according to gender however, revealed a statistically significant association 
between T/T genotype and AD risk in men (AD: 32.4%, HC: 16.9%; p=0.028), in contrast 
with the results in women (AD: 29.6%, HC: 33.8%; p=0.472). 
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 The crude ORs for AD in men conferred by DHCR24 rs600491 genotypes are 
presented in Figure 4. Men with the T/T genotype had a significantly increased risk for AD 
(OR=4.37; p=0.009) considering C/C genotype as reference category (OR=1). The effect of 
the T/T genotype on AD risk was also significant when it was compared to C+ genotypes as 
reference category (OR=1). Logistic regression analysis revealed no interaction between the 
DHCR24 rs600491 and APOE polymorphisms (p=0.856).  
 








All*   
C/C 38 (16.1%) 35 (17.2%) 
C/T 126 (53.4%) 111 (54.4%) 
T/T 72 (30.5%) 58 (28.4%) 
Men#   
C/C 8 (10.8%) 16 (24.6%) 
C/T 42 (56.8%) 38 (58.5%) 
T/T 24 (32.4%) 11 (16.9%) 
Women¤   
C/C 30 (18.5%) 19 (13.7%) 
C/T 84 (51.9%) 73 (52.5%) 
T/T 48 (29.6%) 47 (33.8%) 
*χ2=0.254 (2) p=0.881 
#χ2=7.142 (2) p=0.028 
¤χ2=1.502 (2) p=0.472 
DHCR24: Seladin1 (Selective AD indicator) gene; AD: Alzheimer’s disease; 
















Figure 4. Odds ratios (ORs) with 95% CI for AD conferred by DHCR24 rs600491 





 As shown in Table 8, the different DHCR24 rs638944 genotype frequencies were 
similar in the AD as compared to the HC group, and showed no statistically significant 
difference (p=0.687). Logistic regression analysis revealed no interaction between the 
DHCR24 rs638944 and APOE polymorphisms (p=0.795).  
 








G/G 88 (37.3%) 81 (39.7%) 
G/T 116 (49.2%) 92 (45.1%) 
T/T 32 (13.5%) 31 (15.2%) 
χ2=0.752 (2) p=0.687 
DHCR24: Seladin1 (Selective AD indicator) gene; AD: Alzheimer’s disease; 
HC: Healthy control 
 
III. Neuroinflammation-related polymorphisms 
 
Table 9 presents the genotype distribution of the IFNG, PLA2G4A and PTGS2 
polymorphisms in the investigated groups. The frequencies of the IFNG A/A genotype and 
the A allele were higher in AD as compared to HC group, although the differences did not 
reach statistical significance (p=0.174 for genotypes, p=0.139 for alleles). Comparison of 
PLA2G4A genotype and allele frequencies between AD and HC showed no statistically 
significant difference, although genotype A1/A1 occurred more frequently in AD than in HC 
(p=0.143 for genotypes, p=0.269 for alleles).  
 The PTGS2 G/G genotype was significantly over-represented in AD as compared to 
HC group (AD: 74.7%; HC: 59.6%), while the G/C and C/C genotypes were significantly 
more frequent in HC than in AD group (G/C: AD: 23.6%, HC: 33.1%; C/C: AD: 1.7%, HC: 
7.3%; p<0.001). The PTGS2 allele distribution also showed statistically significant difference 
between cases and controls with higher G allele frequency in the AD group (AD: 86.5%, HC: 
76.1%; p<0.001).  
 The crude ORs for AD conferred by PTGS2 genotypes are presented in Figure 5. The 
effect of the G/G genotype on AD risk was significantly increased (OR=5.46; p=0.003) as 
compared to C/C genotype as reference category (OR=1). The G/G genotype also had a 
significantly increased risk (OR=2.00; p<0.001) when it was compared to C+ genotypes as 
reference category (OR=1). Analyzing the results according to gender and age at onset, no 
interactions among these factors and the investigated polymorphisms (IFNG, PLA2G4A, 
PTGS2) were observed (p>0.1). 
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 In accordance with the genotype frequencies, IFNG A/A, PLA2G4A A1/A1, PTGS2 
G/G genotypes were considered as possible risk factors for AD. The interaction between the 
possible risk factors were investigated in pairs, and none of them contributed significantly to 
the logistic regression model (IFNG*PLA2G4A: p=0.877; IFNG*PTGS2: p=0.245; 
PLA2G4A*PTGS2: p=0.872). Logistic regression analysis also revealed no effect of 
interaction with APOE ε4 allele on AD risk (IFNG*APOE: p=0.132; PLA2G4A*APOE: 
p=0.733; PTGS2*APOE: p=0.482). 
 






IFNG *   
T/T 47 (19.8%) 55 (22.4%) 
T/A 131 (55.3%) 146 (59.6%) 
A/A 59 (24.9%) 44 (18.0%) 
PLA2G4A #   
A1/A1 58 (24.5%) 43 (17.6%) 
A1/A2 97 (40.9%) 116 (47.3%) 
A2/A2 82 (34.6%) 86 (35.1%) 
PTGS2 ¤   
G/G 177 (74.7%) 146 (59.6%) 
G/C 56 (23.6%) 81 (33.1%) 
C/C 4 (1.7%) 18 (7.3%) 
* χ2=3.492 (2) p=0.174 
# χ2=3.886 (2) p=0.143 
¤ χ2=16.318 (2) p<0.001 
HC: Healthy control; AD: Alzheimer’s disease; IFNG: interferon-γ; PLA2G4A: 






















IV. Neuronal dysfunction 
IV.1. Cholinergic system-related polymorphism 
 
CHRFAM7A genotype frequencies are presented in Table 10. Genotype 1 was significantly 
over-represented in AD as compared to HC (AD: 36.0%, HC: 24.0%), while the frequency of 
genotype 3 was significantly lower in AD, than in HC (AD: 12.6%, HC: 22.3%). The 
differences were statistically significant (p=0.011). The crude ORs for AD conferred by 
CHRFAM7A genotypes are presented in Figure 6. The CHRFAM7A genotype 1 had a 
significantly increased risk on AD (OR=2.66; p=0.012) as compared to genotype 3 as 
reference category (OR=1). 
 








1 63 (36.0%) 42 (24.0%) 
2 90 (51.4%) 94 (53.7%) 
3 22 (12.6%) 39 (22.3%) 
χ2=9.025 (2), p=0.011 
AD: Alzheimer’s disease; HC: healthy control; CHRFAM7A: partially 
















Figure 6. Odds ratios (ORs) with 95% CI for AD conferred by CHRFAM7A genotypes 
 
 According to the genotype frequencies CHRFAM7A genotype 1 and APOE ε4 allele 
were considered as possible risk factors for AD. Table 11 summarizes the frequencies and 
ORs for the interaction between APOE ε4 allele and CHRFAM7A genotype 1 in the 
investigated groups. Simultaneous presence of APOE ε4 allele and CHRFAM7A genotype 1 
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occurred more frequently in AD as compared to HC (AD: 12.6%, HC: 4.0%). The ORs for the 
presence of ε4 allele with the CHRFAM7A genotype 1 (OR=6.03, p<0.001) or without the 
CHRFAM7A genotype 1 (OR=6.11, p<0.001) were same values, therefore it is unlikely that 
the combination of these genetic variants would be involved in AD. Logistic regression 
analysis revealed no interaction between the CHRFAM7A and APOE polymorphisms 
(p=0.165). 
 











OR 95% CI p* 
+ + 22 (12.6%) 7 (4.0%) 6.028 2.438-14.902 <0.0001 
+ - 51 (29.1%) 16 (9.1%) 6.114 3.220-11.609 <0.0001 
- + 41 (23.4%) 35 (20.0%) 2.247 1.300-3.883 0.004 
- - 61 (34.9%) 117 (66.9%)  Reference  
The reference category is HC.  * Result of Wald statistics. 
AD: Alzheimer’s disease; HC: Healthy control; APOE ε4: Apolipoprotein E ε4 allele; CHRFAM7A: partially 
duplicated variant of α7 nicotinic acetylcholine receptor subunit gene 
 
 
IV.2. Serotonergic system-related polymorphisms 
 
Table 12 presents the genotype frequencies of the HTR2A and 5HTTLPR polymorphisms in 
the examined groups. Compared with the controls, there was a higher frequency of HTR2A 
C/C genotype and lower frequency of T/T and T/C genotypes in the AD group without 
statistically significant difference (p=0.108). Individuals with at least one T allele were 
grouped together. The analysis was also performed by the presence or absence of the T allele 
in the genotypes, thereby T- (C/C) and T+ (C/T and T/T) genotype categories were 
investigated, and a statistically significant difference was found between cases and controls 
(p=0.037). However, no significant association of HTR2A alleles and the risk for AD was 
observed (p=0.251). 
 The crude ORs for AD conferred by HTR2A genotypes are presented in Figure 7. The 
effects of C/C and C/T genotypes on AD risk were not significant considering T/T genotype 
as reference category (OR=1). However, as compared to the T+ genotypes as reference 
category (OR=1) the HTR2A C/C genotype had a significantly increased risk for AD 
(OR=1.53; p=0.035).  
 The frequency of the different 5HTTLPR genotypes was similar in AD as compared to 
HC, and there was no statistically significant difference (p=0.883). The 5HTTLPR allele 
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distribution also did not show statistically significant difference between the two investigated 
groups (p=0.768). 
 






HTR2A*   
T/T 36 (14.6%) 34 (16.5%) 
T/C 117 (47.4%) 113 (54.9%) 
C/C 94 (38.0%) 59 (28.6%) 
5HTTLPR#   
L/L 78 (31.6%) 64 (31.0%) 
L/S 129 (52.2%) 105 (51.0%) 
S/S 40 (16.2%) 37 (18.0%) 
* χ2=4.459 (2) p=0.108 
# χ2=0.250 (2) p=0.883 
HC: Healthy control; AD: Alzheimer’s disease; HTR2A: serotonin receptor A2; 














Figure 7. Odds ratios (ORs) with 95%CI for AD conferred by HTR2A genotypes 
 
 The presence of the HTR2A C/C and the 5HTTLPR L/L genotypes were considered as 
possible risk factors for AD. Both AD and HC groups were divided into four subgroups 
according to the presence or absence of the HTR2A C/C and 5HTTLPR L/L genotypes. Table 
13 summarizes the frequencies and ORs for the interaction between the probable risk factors 
for AD. Logistic regression analysis revealed an interaction between the 5HTTLPR and the 
HTR2A T102C polymorphisms (p=0.032). The L/L and C/C genotype carriers had a 
significantly increased risk for AD (OR=2.50; p=0.016). The effect of the L/L genotype 
without the C/C genotype and the effect of the C/C genotype among those who do not carry 
the L/L genotype was not significant (OR=0.79; p=0.327; OR=1.16; p=0.524). 
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OR 95% CI p* 
 
+ + 31 (12.6%) 11 (5.3%) 2.499 1.190–5.247 0.016 
+ - 47 (19.0%) 53 (25.7%) 0.786 0.486–1.272 0.327 
- + 63 (25.5%) 48 (23.3%) 1.164 0.730–1.857 0.524 
- - 106 (42.9%) 94 (45.6%) reference 
The reference category is HC.  * Result of Wald statistics  
HC: Healthy control; AD: Alzheimer’s disease; HTR2A C/C: serotonin receptor A2 C/C genotype; 5HTTLPR 
L/L: serotonin transporter gene-linked polymorphic region L/L genotype 
 
 
 Stratification of HTR2A and 5HTTLPR data according to APOE ε4 status (individuals 
with one or two ε4 alleles vs. individuals with no ε4 allele) did not reveal interaction either 
between HTR2A and APOE (p=0.690) or between 5HTTLPR and APOE (p=0.859). There 
was also no statistically significant difference of age at onset for AD if we compared the mean 
ages for the different HTR2A and 5HTTLPR genotypes (p>0.05). 
 
IV.3. Brain-derived neurotrophic factor polymorphism 
 
The BDNF Val66Met genotype frequencies observed in the investigated groups are presented 
in Table 14. The frequency of the BDNF Val/Val homozygous genotype was significantly 
higher in AD than in the HC group (AD: 58.8%, HC: 31.7%; p<0.0001). There were also 
robust differences in the distribution of the Val/Met and Met/Met genotypes in AD versus HC 
(Val/Met: AD: 35.0%, HC: 48.2%; Met/Met: AD: 6.2%, HC: 20.1%; p<0.0001).  
 The crude ORs for AD conferred by BDNF genotypes are presented in Figure 8. The 
effect of the Val/Val genotype on AD risk was significantly increased (OR=5.97; p<0.001) as 
compared to Met/Met genotype as reference (OR=1). The Val/Val genotype also had a 
significantly increased risk (OR=3.07; p<0.001) when it was compared to Met+ genotypes as 
reference (OR=1). The Val allele was significantly over-represented in AD as compared to 
HC (AD: 76.2%, HC: 55.8%; p<0.0001). 
  Table 15 summarizes the frequencies and ORs for the interaction between the APOE 
ε4 allele and BDNF Val/Val genotype in the examined groups divided into subgroups 
according to the presence of the ε4 allele (one or two) and the presence of the Val/Val 
genotype. Genotypes containing both the ε4 allele and BDNF Val/Val genotype occurred 












Val/Val 94 (58.8%) 52 (31.7%) 
Val/Met 56 (35.0%) 79 (48.2%) 
Met/Met 10 (6.2%) 33 (20.1%) 
χ2=28.258 (2), p<0.0001 
HC: Healthy control; AD: Alzheimer’s disease; 
















Figure 8. Odds ratios (ORs) with 95%CI for AD conferred by BDNF genotypes 
 
 The interaction between the BDNF and APOE polymorphisms did not contribute 
statistically significantly to the logistic regression model (p=0.135). The OR for the presence 
of both the ε4 allele and BDNF Val/Val genotype in the AD group was 26.05 as compared to 
patients with neither the ε4 nor the BDNF Val allele. Since in AD, the OR for the occurrence 
of the ε4 allele and BDNF Val/Val genotype was much higher than the OR for the presence of 
the ε4 allele without the Val/Val genotype, we propose a synergistic effect of the two SNPs 
on the risk for AD. Furthermore, the crude ORs for the effect of the BDNF Val/Val genotype 
investigating in itself (OR: 3.07) and the APOE ε4 allele investigating in itself (OR: 5.37) 
were remarkably lower than the adjusted OR for their combined effect (OR: 26.05). 
 










OR 95% CI p 
+ + 33 (20.6%) 3 (1.8%) 26.053 7.530-90.139 <0.0001 
+ - 28 (17.5%) 22 (13.4%) 3.014 1.535-5.920 0.001 
- +  61 (38.1%) 49 (29.9%) 2.948 1.729-5.029 <0.0001 
- - 38 (23.8%) 90 (54.9%) Reference  
The reference category is HC.  * Result of Wald statistics. 
AD: Alzheimer’s disease; HC: Healthy control; APOE ε4: Apolipoprotein E ε4 allele; BDNF Val/Val: brain-






We found the expected statistically significant APOE ε4 allele elevation in AD as compared 
to the HC group. These results are in line with former findings for the Hungarian population 
(Kálmán et al., 1997; Janka et al., 2002; Juhász et al., 2005) and with results on other ethnic 
groups (Lung et al., 2005; Murrell et al., 2006; Sando et al., 2008). The reported ε4 allele 
frequencies for patients with AD show a wide range of variance from 19 to 55% even within 
Europe, however these are the end values and they are generally between 30 and 45%. The 
Caucasian population is not homogeneous and the Hungarian population is genetically 
different from other European ethnic groups. According to our results, the ε4 allele frequency 
in Hungarians is lower as compared to the average ε4 allele frequency of other Caucasian 
populations (Table 16). The different association studies including our study are consistent 
however, since significantly higher ε4 allele frequency was found in AD compared to healthy 
controls in each population. 
 
 Table 16. ApoE ε4 allele frequencies in AD in different populations 
   
Population ε4 allele frequency 
 in AD* 
Caucasian  37% 
Benjamin, 1995 Norway 34% 
Chartier-Harlin, 1994 UK 29% 
Chartier-Harlin, 1994 France 24% 
Kuusisto, 1994 Finland 36% 
Lehtimaki, 1995 Finland 55% 
Sorbi, 1994 Italy 19% 
Present study Hungary 28% 
Asian  28% 
African descent  35% 
Hispanic  24% 
  *Data are from www.alzgene.org; AD: Alzheimer’s disease 
 
 
 Our findings confirm the results of genetic and epidemiological studies reporting that 
the ε4 allele is the most important known risk factor for late-onset sporadic AD. The presence 
of the ε4 allele increases the risk and reduces the age at onset of dementia, in contrast to the 
possession of the ε2 allele that has a protective effect. Our data partly confirmed the effect of 
gender on AD risk, since we found an increased predisposition to AD in ε4/ε4 homozygote 
women as compared to ε4/ε4 homozygote men, but the same risk for AD in women carrying 
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the ε3/ε4 genotype as compared to men with the ε3/ε4 genotype. Our results support the dose 
dependent risk of APOE ε4 allele for AD, in view of the fact that we found significantly 
increased risk for AD in ε4 homozygotes as compared to ε4 heterozygotes (Figure 2). 
 APOE ε4 isoform has been demonstrated to negatively influence and intensify the 
biochemical disturbances of AD, including Aβ deposition, tangle formation, neuronal cell 
death, dysfunction of lipid homeostasis and cholinergic signaling (Cedazo-Mínguez and 
Cowburn, 2001). The APOE ε4 isoform associated neuropathology is most likely attributable 
to its conformational specificity defined by the amino acid change at residues 112 and 158 
(Mahley et al., 2006). APOE ε3 has Cys-112 and Arg-158, while ε2 has Cys and ε4 has Arg at 
both positions. In ε4 isoform Arg-112 mediates the interaction between the two structural 
domains of APOE: the N-terminal domain containing the low-density lipoprotein receptor and 
the C-terminal domain containing the major lipid binding site (Mahley et al., 2006). The ε2 
and ε3 isoforms are much less likely to undergo domain interaction than ε4. In cultured 
neuronal cell study exogenous APOE ε4 increased the Aβ generation more as compared to 
exogenous ε3, but when domain interaction was blocked within ε4, this difference was not 
detected between the two isoforms (Ye et al., 2005). 
 
I. Amyloid-β metabolism-related polymorphisms 
 
 Our findings failed to support the hypothesis that BACE1 C786G and PLAU 
Pro141Leu polymorphisms confer susceptibility to AD, since we did not find statistically 
significant differences neither in genotype nor in allele distribution comparing the AD and the 
HC groups. We did not detect genetic interaction between the BACE1 and the APOE 
genotypes or between the PLAU and the APOE genotypes in the development of AD. 
 We also failed to support the hypothesis that CALHM1 rs2986017 polymorphism at 
10q24 is associated with late onset AD, since comparing the AD and the HC groups we found 
no significant differences either in genotype or in allele distribution. Only a very modest, 
marginally significant effect of the Leu+ genotypes on AD was observed. 
 Dreses-Werringloer and co-workers (2008) examined this polymorphism in five 
Caucasian AD and control samples, and found that the Leu allele is associated with the risk 
for AD (Dreses-Werringloer, et al, 2008). Further studies including ours, however, did not 
corroborate this observation. Bertram et al (2008) investigated several independent datasets of 
Caucasian patients and controls and found no association between rs2986017 polymorphism 
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and AD (Bertram et al, 2008). The CALHM1 genotype distribution reported by Minster and 
co-workers (2009) looks very similar to that found by Sleegers et al (2009) and Beecham et al 
(2009) without any statistically significant difference comparing the case and the control 
groups. 
 There are also contradictory reports on the correlation between the CALHM1 
polymorphism and the age at onset of AD. The Dreses-Werringloer study (2008) showed 
evidence for the association between the Leu/Leu genotype and an earlier onset of AD 
(Dreses-Werringloer, et al, 2008), but in another paper only a modest correlation was reported 
(Minster et al, 2009). 
 Although the effect of the CALHM1 Leu allele on AD in itself in our study was found 
to be small and only marginally significant, we hypothesized that in combination with the 
APOE ε4 allele it may increase the effect of the ε4 allele occurring on its own. We failed to 
detect a genetic interaction between the CALHM1 Leu allele and the APOE genotypes in the 
development of AD. Despite the modest correlation between the presence of the Leu allele 
and AD, this study does not support the involvement of CALHM1 rs2986017 polymorphism 
in the aetiology of AD. 
 
II. Cholesterol metabolism-related polymorphisms 
 
Our results indicate a gender dependent effect of DHCR24 rs600491 polymorphism on the 
susceptibility to AD. A statistically significant correlation was found in men between the T/T 
genotype and the risk for AD, whereas this association was not observed in the whole 
population or in women. Men with the T/T genotype had a significantly increased risk for AD 
as compared to those men carrying the C allele. Our findings on DHCR24 rs600491 
polymorphism are in line with the study of Lämsä and co-workers (2007) that was also 
reported an increased risk for AD in men carrying the T/T genotype. 
 We failed to support the hypothesis that DHCR24 rs638944 polymorphism influences 
the predisposition to AD, since we did not observe statistically significant differences neither 
in genotype nor in allele distribution comparing the AD and the HC groups. We also failed to 





III. Neuroinflammation-related polymorphisms 
 
Our results indicate that PTGS2 G/G genotype can confer susceptibility to AD and the 
possession of the C allele can have a protective effect. In case of the IFNG and the PLA2G4A 
polymorphisms, we did not find statistically significant differences neither in genotype nor in 
allele distribution comparing the AD and the HC groups. We also did not detect an epistasis 
between the investigated polymorphisms in the development of AD.  
 The genotype distribution of PTGS2 in this study is very similar to that was found by 
Abdullah and co-workers in a Caucasian case-control sample from Florida (Abdullah et al., 
2006). We confirmed their findings in a Hungarian sample. The investigated PTGS2 promoter 
polymorphism has functional consequence, since the C allele was reported to have a 
significantly lower promoter activity in human lung fibroblasts (Papafili et al., 2002). In 
agreement with this observation, higher PTGS2 expression and PGE2 levels were measured 
in monocytes from probands with G/G genotypes as compared to probands having G/C or 
C/C genotypes (Cipollone et al., 2004). 
 There are conflicting reports on PTGS2 mRNA level in AD brain, as both increased 
and decreased levels were reported compared to healthy brain samples (Heneka and 
O’Banion, 2007). PTGS2 expression seems to vary with the severity of the disease with 
increased PTGS2 mRNA level in the early stage of AD (Hoozemans et al., 2008). The main 
activity of non-steroidal anti-inflammatory drugs (NSAIDs) is to inhibit PTGS activity, the 
traditional NSAIDs act on both the constitutive PTGS1 and the induced PTGS2 isoforms. 
According to epidemiological studies the long-term use of traditional NSAIDs can reduce the 
risk of developing AD and can delay its onset (McGeer and McGeer, 2007). Compared with 
non-users, 50% lower risk of being affected by AD has been reported for long-term NSAID 
users (Landi et al., 2003). However, this protective effect is not yet confirmed with specific 
PTGS2 inhibitors, it has been reported that daily celecoxib (primarily inhibits PTGS2) use 
may improve cognitive performance and increase regional brain metabolism in people with 
age-associated memory decline (Small et al., 2008). 
 PTGS2 is an interesting candidate gene for AD on account of its chromosomal 
location and physiological function. The gene encoding PTGS2 maps to 1q25.2-q25.3, which 
is located in a repeatedly established AD linkage region (Liu et al., 2007; Butler et al., 2009).  
 Since the C/G and C/C genotypes were over-represented in the HC as compared to the 
AD group, the C allele appeared to reduce the risk for developing AD. Possible explanation 
for the protective effect of the PTGS2 C allele could be that due to its reduced promoter 
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activity, in the early stages of AD the PTGS2 expression in individuals with the C allele is not 
as high as in patients with the G/G genotype. The intensity of PTGS2 expression can 
influence the extent of inflammatory response, which may interact with other pathological 
processes in AD.   
 Our findings do not confirm the hypothesis that the investigated IFNG and PLA2G4A 
polymorphisms are associated with late onset AD. The results indicate however, that PTGS2 
G-765C promoter polymorphism influences the risk for AD, and supports the involvement of 
PTGS2 in the aetiology of AD.  
 
IV. Neuronal dysfunction 
IV.1. Cholinergic system-related polymorphism 
 
The CHRFAM7A genotype without the -2bp allele was significantly over-represented in AD 
as compared to the controls. According to our results, the partially duplicated variant of the α7 
nAChR subunit gene can be a strong candidate gene for AD. It was demonstrated that 
CHRFAM7A are transcribed, but there is no evidence whether this transcript is translated or 
not (Gault et al, 1998; Riley et al, 2002). It is unlikely that this hybrid gene functions as a 
nicotinic receptor due to the absence of signal peptide, glycosylation site and part of the 
ligand-binding site encoded by exons 1-4 (Leonard and Freedman, 2006). It is possible 
however, that if CHRFAM7A is translated, the gene product is able to interact with α7 
polypeptide, since most of the contact regions are encoded in exon 5-10 (Riley et al, 2002).  
 The mechanism by which the -2bp allele variant of duplicated exon 6 decreases the 
risk of AD remains to be established. The -2bp deletion results in a stop codon within exon 6, 
therefore the putative translational product will be truncated. Possible explanation could be 
that the wild type CHRFAM7A gene product may alter the normal assembly of the α7 nAChR 
which could be avoided by the truncated gene product (Riley et al, 2002). This hypothesis is 
also supported by the observation that the deletion of the CHRNA7 gene improves cognitive 
deficits and synaptic pathology in a mouse model of Alzheimer's disease (Dziewczapolski et 
al., 2009). 
 Besides AD we investigated the CHRFAM7A polymorphism in other dementias such 
as dementia with Lewy bodies (DLB), Pick’s disease (PiD) and vascular dementia (VD), 
respectively (Fehér et al., 2009a). Similar to AD, DLB and PiD are also neurodegenerative 
disorders associated with abnormal protein aggregations and inclusion body formation. DLB 
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pathology is characterized by abnormal aggregations of α-synuclein termed Lewy bodies 
(Neef and Walling, 2006). The term “Pick’s disease” is restricted to cases showing lobar 
atrophy with Pick bodies composed of numerous randomly oriented hyperphosphorylated tau 
fibrils (Frederick, 2006), and PiD is included in the nomenclature of frontotemporal dementia 
(Lund and Manchester Research Groups, 1994). VD results from various cerebrovascular 
diseases leading to cognitive impairment which depends on the severity and location of 
lesions (Black, 2007). 
 In an experimental system, Aβ effectively induced tau phosphorylation via α7 nAChR 
that could be decreased by α7 nAChR antagonists. Aβ - α7 nAChR interaction activates 
mitogen-activated cascade protein which is a tau protein kinase (Wang et al., 2003). Although 
the α7 nAChR-mediated and Aβ induced tau phosphorylation seemed to be a normal 
reversible cellular response, the above mentioned findings suggest that α7 nAChR may be 
implicated in neuropathological conditions associated with abundant Aβ and/or abnormal 
functions of tau protein. Abnormal α7 nAChR physiology and loss of neurons expressing α7 
nAChR may contribute to memory and cognition impairment (Wang et al., 2003). 
 The CHRFAM7A genotype without the -2bp allele was significantly over-represented 
in DLB and in PiD compared to healthy controls. The absence of the -2bp allele in DLB and 
especially in PiD occurred even more frequently than in AD. However, the small sample size 
for DLB and PiD can influence the results of the statistical analyses. The CHRFAM7A 
genotype frequencies showed no significant differences between VD and HC (Fehér et al., 
2009a).  
 There may be a functional relationship between Aβ, α7 nAChR and tau protein, since 
it has been reported that Aβ - α7 nAChR interaction can activate tau phosphorylation (Wang 
et al., 2003). This relationship can be the common feature by which genetic variants of 
CHRFAM7A can influence the risk either for AD, DLB or for PiD. Aβ is the major 
component of senile plaques implicated in AD and DLB, and the hyperphosphorylated tau 
protein is the main constituent of neurofibrillary tangles in AD brains and Pick bodies 
occurring in PiD. 
 Although these findings may suggest that the CHRFAM7A -2bp deletion 
polymorphism can be implicated not just in AD, but in DLB and PiD as well, additional 
studies are required to increase number of cases, and to investigate the copy number 
polymorphism of CHRFAM7A. According to our findings it is unlikely that the -2bp deletion 




IV.2. Serotonergic system-related polymorphisms 
 
Our results indicate that the HTR2A T102C polymorphism may influence the susceptibility to 
AD, especially in combination with the 5HTTLPR L/L genotype. Although we did not detect 
statistically significant differences in the HTR2A genotype distribution between AD and HC 
groups, an association was found between the C/C genotype and the risk for AD when we 
conducted the C/T and T/T genotypes. 
 However, we did not find significant correlation between AD and the HTTLPR 
polymorphism in itself, we hypothesized that in combination with the HTR2A C/C genotype 
it may increase the effect of the C/C genotype occurring on its own. Our results confirm the 
earlier findings of an increased frequency of the co-presence of the L/L and C/C genotypes in 
AD as compared to HC group (Micheli et al., 2006). We found that the simultaneous 
occurrence of the HTTLPR L/L and HTR2A C/C genotypes enhance the risk 2.5-fold for the 
development of AD. The Micheli study (2006) reported a significant eightfold higher risk for 
AD in case of simultaneous presence of the L/L and C/C genotypes. 
 These findings can be of considerable relevance given the fact that both 
polymorphisms are functional and both act on the same biological pathway, namely 
serotonergic transmission. The HTR2A gene activity of the C allele was proved to be 
significantly decreased as compared to the T allele, therefore in individuals with the C/C 
genotype less receptor may be available for 5HT than in C/T or T/T carriers. The 5HTTLPR 
polymorphism determines dose-dependent 5HT reuptake from the synaptic cleft, being the S 
allele less effective than the L allele. In summary, in case of simultaneous presence of the 
HTR2A C/C and the 5HTTLPR L/L genotypes, the serotonergic transmission may be less 
effective as compared to the other combinations of HTR2A and 5HTTLPR genotypes. 
 
IV.3. Brain-derived neurotrophic factor polymorphism 
 
Our results revealed that the Val66Met polymorphism of the BDNF gene may be implicated 
in the susceptibility to AD, since we have found that the Val/Val genotype and the Val allele 
occurred with significantly higher frequency in AD than in HC. Japanese and Italian studies 
have also reported this association (Ventriglia et al., 2002; Matsushita et al., 2005), although 
another Japanese and a Spanish study failed to find the same results (Combarros et al., 2004; 
Akatsu et al., 2006). The frequency of the Val allele in the Hungarian AD group in this study 
was similar to the data published for Italian and Spanish populations (Hungarian: 76%; 
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Italian: 78%; Spanish: 79%). While in the Japanese population, Matsushita and co-workers 
(2005) reported 61%, Akatsu et al (2006) reported 57% frequency for the occurrence of the 
Val allele in AD. In contrast to the findings in the AD group, the distribution of the Val allele 
among the Hungarian HC probands was closer to the results found in the Japanese HC groups 
[Hungarian: 56%; Japanese (Matsushita et al., 2005): 56%; Japanese (Akatsu et al., 2006): 
57%; versus Italian: 70%; Spanish: 81%]. According to these findings, the BDNF Val66Met 
polymorphism is highly heterogeneous among the different ethnic populations, even within 
Europe.  
 BDNF is important for memory-related hippocampal processes. The functional 
Val66Met polymorphism of BDNF can influence the activity-dependent BDNF secretion, 
thus it can impact on hippocampal activity. Egan et al. (2003) reported impaired episodic 
memory in Met allele carrier healthy probands and found that neurons transfected with 
BDNFMet showed lower depolarization-induced secretion of BDNF. These results are 
consistent with another study that demonstrated reduced hippocampal activity during 
declarative memory processing in Met allele carrier probands (Hariri et al., 2003). According 
to our findings and other association studies, the Val allele is associated with AD (Combarros 
et al., 2004; Matsushita et al., 2005).  
 The decreased BDNF level in AD reported by several studies (Ferrer et al, 1999; 
Holsinger et al., 2000) can be the result of the neurodegenerative processes, the loss of 
neurons producing BDNF and therefore it can be independent of the BDNF genotype. In the 
early stage of AD higher BDNF level was measured than in HC (Laske et al., 2006), which 
can be influenced by the level of the regulated secretion of BDNF, and therefore the BDNF 
Val66Met genotype. A possible explanation of the contradictory observations and the role of 
the BDNF Val66Met polymorphism in AD need further investigation. 
 Besides AD we investigated the BDNF Val66Met polymorphism in DLB and PiD as 
well (Fehér et al, 2009b), and we found that it does not confer susceptibility to DLB. The 
BDNF Val66Met genotype frequencies did not differ significantly either in our, or in a 
Japanese study (Akatsu et al., 2006). The distribution of the Val allele in the Hungarian DLB 
and HC groups was similar to the Japanese data (Hungarian DLB: 52%; Japanese DLB: 60%; 
Hungarian HC: 56%; Japanese HC: 55%). The heterozygous Val/Met genotype occurred in 
PiD with statistically significantly higher frequency as compared to HC, but we have not 
found significant difference in the distribution of BDNF alleles. The small sample size for 
DLB and PiD can influence the results of the statistical analyses therefore these findings 
generate hypothesis and further investigations are required. 
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V. Genetic interactions 
 
Increasing body of evidence supports the complex genetic model of AD, which suggests that 
polygenic network of susceptibility genes may underlie the disease. Since the predisposing 
gene variants confer only fractional risk, genetic interactions may have a major role in 
contributing to neurodegeneration in AD. Figure 9 summarizes and illustrates the assumed 
interactions between the investigated gene polymorphisms of this study. The interactions were 
investigated in pairs of polymorphisms, and the pairs were selected on the basis of the same 
chromosomal localization and/or on the involvement of the same pathogenic mechanism in 
AD. 
  
Figure 9. Interactions between the investigated polymorphisms 
The interactions between the polymorphisms were investigated in pairs depicted 
by the lines connecting them. The p values came from logistic regression analyses. 
 
 
 The interaction was clearly demonstrable in case of the investigated serotonin-related 
genes. Logistic regression analysis revealed an interaction between the 5HTTLPR and the 
HTR2A polymorphisms. The simultaneous presence of the 5HTTLPR L/L and HTR2A C/C 
genotypes increase the risk for AD 2.5-fold, while the effects of L/L or C/C genotypes on AD 
risk analyzed separately on the risk for AD were not statistically significant. 
 According to the logistic regression model there is no interaction between the BDNF 
and APOE polymorphisms. However, considering the calculated effect sizes, it is presumable 
that the interaction between the BDNF and APOE polymorphisms would be statistically 
verifiable by increasing the number of cases. The adjusted ORs for the different BDNF and 
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APOE genotype combinations suggest a synergistic effect between the BDNF and APOE 
polymorphisms. The OR for the presence of both the APOE ε4 allele and BDNF Val/Val 







 Our results confirm the previous findings that APOE ε4 allele confers an allele 
dose dependent risk for AD. 
 We failed to detect association between BACE1 C786G, PLAU Pro141Leu and 
CALHM1 Leu86Pro polymorphisms and the risk for AD. 
 Our findings indicate a gender dependent effect on AD risk with increased 
susceptibility to AD in men carrying the T/T genotype of the DHCR24 rs600491 
polymorphism. 
 We failed to detect association between IFNG T874A and PLA2G4A BanI 
polymorphisms and the risk for AD. 
 We found that the PTGS2 G/G genotype can confer susceptibility to AD and the 
possession of the C allele can have a protective effect. 
 According to our results the -2bp deletion polymorphism of CHRFAM7A can be 
implicated in AD. 
 Our study demonstrates an interaction between 5HTTLPR L/L and HTR2A C/C 
genotypes that seems to increase the risk for AD. 
 We suggest that the BDNF Val/Val genotype in itself and in combination with the 
APOE ε4 allele can be risk factor for AD. 
 In summery, our results support the involvement of the following genes in AD 
aetiology: APOE, DHCR24, PTGS2, CHRFAM7A, HTR2A in epistasis with 










A deviation from the HWE was detected in IFNG genotype distribution in the HC and in 
PLA2G4A genotype distribution in the AD group. Deviation from HWE may indicate 
disturbing influences on the investigated group including selection, limited population size, 
random genetic drift or gene flow. The failure in these assumptions of HWE unlikely affects 
our sample, and all the other genotype distributions were in HWE for cases and controls, 
respectively. A probable explanation for the deviation from HWE may be an error in 
genotyping, therefore in case of IFNG and PLA2G4A polymorphisms the genotyping 
procedure and the results were double checked, and no error was found in the genotyping. 
 A possible limitation of our study is the relatively low number of cases that may 
influence the statistical analyses. In case of BACE1, PLAU, DHCR24, IFNG, PLA24A, 
HTR2A and HTTLPR polymorphisms the post hoc power analyses did not reveal sufficient 
power size (<0.8) which may lead to false negative results, therefore further investigations are 
required with increased number of cases. 
 Case-control association studies have been criticized for conflicting results that may 
arise from heterogeneity in sampling strategies, in the clinical profiles or ethnical background 
of patients compared with inappropriate group of controls incorrectly matched with patients. 
In our study these biases were attempted to be avoided by investigating well defined AD cases 
and appropriately matched (in the aspect of age, gender and ethnicity) healthy, cognitively 
intact control group. Misleading findings can also arise from linkage disequilibrium. If 
association is found with a polymorphism, the functional variant may be located either at the 
polymorphic site under study or at another polymorphic site somewhere else in the same gene 
or in a nearby gene. Thereby further investigations addressing other polymorphisms in the 
investigated genes are required. 
 An extension of our work would be the option to make use of the genetic analysis in 
homogeneous subgroups of AD patients defined by quantitative traits underlying disease 
syndromes. The genetic investigation of such endophenotypes would offer an alternative or a 
complement to studies of categorical disease phenotypes. 
 Notwithstanding, the main advances of this study are: 1.) Genotype distributions of 
different polymorphisms seem to depend on ethnic backgrounds, and our study (except for 
APOE polymorphism) are the first report on the Hungarian population in AD. 2.) Well 
defined AD cases were compared with appropriately matched (in the aspect of age, gender 
and ethnicity) healthy, cognitively intact control group. 3.) This is the first study on 
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PLA2G4A BanI polymorphism in AD. 4.) In case of APOE, DHCR24, PTGS2, BDNF 
polymorphisms we could clearly confirm the previous positive findings in an independent 
population. 5.) An interaction between the HTR2A and the HTTLPR polymorphisms was 
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Association Between BDNF Val66Met Polymorphism and
Alzheimer Disease, Dementia With Lewy Bodies,
and Pick Disease
A´gnes Fehe´r, Anna Juha´sz, A´gnes Rimano´czy, Ja´nos Ka´lma´n, and Zolta´n Janka
Abstract: A functional polymorphism of the brain-derived
neurotrophic factor (BDNF Val66Met) has been reported to aﬀect
memory-related hippocampal activity. Apolipoprotein E (ApoE)
gene polymorphism is known to be associated with Alzheimer
disease (AD), dementia with Lewy bodies (DLB), and Pick disease
(PiD). We tested the hypothesis that BDNF Val and ApoE e4
alleles confer susceptibility to AD, DLB, and PiD. The study
included 160 AD, 34 DLB patients, 38 autopsy-conﬁrmed PiD, and
164 age-matched healthy control (HC) probands. The frequency of
the BDNF Val allele was signiﬁcantly higher in AD, but there were
no statistical diﬀerences in the allele distribution in PiD or in DLB
as compared with HC. The Val/Met genotype occurred with
statistically signiﬁcantly higher frequency in PiD than in HC. The
ApoE e4 allele was signiﬁcantly overrepresented in all dementias as
compared with HC. Genotypes containing both ApoE e4 and
BDNF Val alleles occurred more frequently in all investigated
dementias than in HC. We suggest that the presence of the BDNF
Val allele in itself and in combination with the ApoE e4 allele can
be risk factors for AD, and the results indicate a synergistic eﬀect of
the 2 polymorphisms on DLB and PiD risk.
Key Words: apolipoprotein E (ApoE) polymorphism, brain-
derived neurotrophic factor (BDNF) Val66Met polymorphism,
Alzheimer disease, dementia with Lewy bodies, Pick disease
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Alzheimer disease (AD), dementia with Lewy bodies(DLB), and Pick disease (PiD) are neurodegenerative
diseases that seem to have common features at cellular and
molecular levels including protein aggregation and inclu-
sion body formation. These inclusions probably represent
an end stage of a molecular cascade.1 AD involves 2 major
kinds of protein aggregations: extracellular senile plaques
containing b-amyloid and intracellular neuroﬁbrillary
tangles of the microtubular protein t.2 DLB is a synuclei-
nopathy, a neurodegenerative condition associated with
abnormal aggregations of a-synuclein.3 Similar to AD, PiD
is taupathy: its pathologic features imply the presence of
neuronal inclusions called Pick bodies, which are composed
of numerous randomly oriented t ﬁbrils.4
The brain-derived neurotrophic factor (BDNF) is a
member of the neurotrophin family of growth factors,
produced by cortical neurons. Besides its general role in
neurodevelopment, BDNF has important functions in the
adult brain such as promoting the survival and maintaining
the structural integrity of neuronal cells.5 The activity-
dependent expression of BDNF plays a role in modulating
synaptic changes associated with learning and memory.6
Several studies have suggested that the altered functioning
of BDNF could be involved in the pathogenesis of
neurodegenerative disorders. It has been reported that
patients with AD have reduced BDNF levels in the
hippocampus and in the temporal cortex compared with
healthy controls (HCs).7
The BDNF gene encodes a precursor peptide (pro-
BDNF) that is secreted and cleaved by extracellular
protease to form the mature BDNF protein.8 A single
nucleotide polymorphism (SNP) at nucleotide 196 (G/A)
producing a nonconservative amino acid substitution at
codon 66 (Val/Met) has been identiﬁed.9 Although this
SNP is located in the 50 pro-BDNF sequence and does not
aﬀect the function of the mature BDNF, it has a major
impact on the intracellular traﬃcking and regulated
secretion of pro-BDNF.10 Genetic inﬂuences on BDNF
secretion can lead to alterations in hippocampal activity.
The BDNF Val66Met polymorphism has been found to be
associated with episodic memory and hippocampal func-
tion.11 There are conﬂicting reports on the correlation
between AD and BDNF Val66Met. Association studies
have reported that the Val allele occurs with signiﬁcantly
higher frequency in AD as compared with HCs.12,13
However, other authors have not found such a correla-
tion.9,14
Apolipoprotein E (ApoE) is involved in lipid transport
and metabolism. In addition, it plays a speciﬁc role in the
central nervous system, including neuronal development,
regeneration, and certain neurodegenerative processes. The
polymorphism of the ApoE gene determines 3 isoforms of
ApoE protein (e2, e3, and e4) with diﬀerent conformation
and lipid binding properties.15 The e3 allele is the most
prevalent form, and the proportion of the 3 alleles diﬀers
between populations. ApoE e4 allele carriers have an
increased risk of several neurodegenerative disorders, but
the most well known one is the association between the e4
allele and AD.16 There are contradictory reports on the
association between the e4 allele and DLB.17,18 Association
studies have reported that the e4 allele is signiﬁcantly
overrepresented in PiD19,20 and the number of e4 alleles was
inversely related to the onset of PiD.19
Both ApoE and BDNF Val66Met genotype frequen-
cies depend on ethnic background. The Hungarian popula-
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tion has been reported to be genetically diﬀerent from other
European ethnic groups.21 The aim of our investigation was
to provide data on ApoE and BDNF Val66Met poly-
morphisms in the Hungarian population. We tested the
hypothesis that the ApoE e4 and BDNF Val alleles confer
susceptibility to AD and to the rare PiD and DLB, from
which very few genetic data are available. Furthermore, we
investigated the interaction between the ApoE e4 and
BDNF Val alleles in the above-mentioned diseases.
SUBJECTS AND METHODS
Probands were whites living in Hungary. The study
included 160 AD patients from the Department of
Psychiatry, Memory Clinic, University of Szeged, who
met the NINCDS/ADRDA criteria for probable AD.22
The DLB group consisted of 34 probands, who were
patients of the Department of Psychiatry and Psychother-
apy, Semmelweis Medical University, Budapest. The
diagnosis was established according to the McKeith
criteria.23 In 20 of the DLB cases, the clinical diagnosis
was veriﬁed by postmortem examination as well. The 38
PiD samples were from the tissue bank at the Department
of Neuropathology, National Institute of Psychiatry and
Neurology, Budapest. The clinical diagnoses were veriﬁed
by postmortem examination. The 164 age and sex-matched
HC probands were selected from spouses of patients at the
Department of Psychiatry, Memory Clinic, University of
Szeged. Informed consent was obtained from the living
subjects included in this study and all protocols were
approved by the local ethical committee.
Mini Mental State Examination (MMSE) scores lower
than 24 were considered characteristic of dementia. The
MMSE scores in the HC group were higher than 28 points
(mean: 29.1±0.9) and none of the probands had any
veriﬁed symptoms of dementia. The mean MMSE score in
the DLB group was 18.5±5.8. In the AD group, it was
17.9±6.1 points. For the PiD group we have no MMSE
data. The characteristics of the probands are presented in
Table 1.
DNA was extracted from peripheral blood leukocytes
according to a standard procedure using the Roche kit. In
the PiD cases, DNA was extracted from paraﬃn-embedded
brain tissues using the EZNA kit (PeqLab Biotechnologie
GmbH). It would be more correct to compare brain
samples of PiD patients with brain samples of HC subjects,
but it has been shown24,25 that regardless of the origin of
the sample, the genotypic concordance is at least 97%.
ApoE genotyping was conducted by polymerase chain
reaction as described earlier26 Genotyping of the BDNF
Val66Met polymorphism was performed by polymerase
chain reaction ampliﬁcation and enzymatic digestion with
restriction enzyme PmaCI, followed by polyacrylamide gel
electrophoresis with ethidium bromide staining.27
The ApoE and BDNF genotype and allele frequencies
were compared using Pearson w2 test. A multinomial
logistic regression model was used to test for the interaction
between the ApoE e4 and BDNF Val alleles. The
signiﬁcance level was set at P<0.05. The program SPSS
15.0 was used for all statistical analyses.
RESULTS
The BDNF Val66Met genotype and allele frequencies
are presented in Table 2. The frequency of the BDNF Val/
Val homozygous genotype was signiﬁcantly higher in AD
than in the HC group (AD: 58.8%, HC: 31.7%), but it
occurred in DLB and especially in PiD with a lower
frequency than in the HC group (DLB: 17.7%, PiD: 5.3%).
There were also robust diﬀerences in the distribution of the
Val/Met and Met/Met genotypes in AD versus HC (Val/
Met—AD: 35.0%, HC: 48.2%; Met/Met—AD: 6.2%,
HC: 20.1%). The Val/Met genotype occurred with sig-
niﬁcantly higher frequency in PiD than in HC (PiD: 78.9%,
HC: 48.2%). The Val allele was signiﬁcantly overrepre-
sented in AD, but there were no statistical diﬀerences in its
occurrence either in DLB or in PiD as compared with HC
(AD: 76.2%, DLB: 51.5%, PiD: 44.7%, and HC: 55.8%).
The ApoE genotype and allele distribution is shown in
Table 3. Among the patients with dementia, no ApoE e2/e2
carriers were detected, and even in the HC group only 2
cases were found. The heterozygous e2/e3 genotype also
occurred with low frequency in AD, DLB, and PiD (AD:
6.2%, DLB: 2.9%, and PiD: 5.3% vs. HC: 14.7%). The e3/
e4 genotype and the e4 allele were signiﬁcantly over-
represented in all groups of dementia compared with HC
(e3/e4 genotype—AD: 30.0%, DLB: 50.0%, PiD: 52.6%,
and HC: 12.8%; e4 allele—AD: 24.1%, DLB: 27.9%, PiD:
40.8%, and HC: 8.9%). Furthermore, the frequency of the
e3/e4 genotype in PiD and DLB was much higher than in
AD. The PiD cases showed a great diﬀerence in the
distribution of the e4 allele not just from HC, but also from
the other 2 dementias.
Table 4 summarizes the frequencies and odds ratios
(ORs) for the interaction between the ApoE e4 and BDNF
Val alleles in the groups of diﬀerent dementias and HC
TABLE 1. Characteristics of the Probands
HC AD DLB PiD
n=164 n=160 n=34 n=38
Age (y) 71.7±8.5 73.7±9.5 76.7±7.2 70.0±8.3
Male/female 63/101 57/103 15/19 12/26
MMSE (scores) 29.1±0.9 17.9±6.1 18.5±5.8 —
AD indicates Alzheimer disease; DLB, dementia with Lewy bodies; HC,
healthy control; MMSE, Mini Mental State Examination; PiD, Pick disease.
TABLE 2. BDNF Val66Met Genotype and Allele Frequencies in
Different Groups










Val/Val 52 (31.7) 94 (58.8) 6 (17.7) 2 (5.3)
Val/Met 79 (48.2) 56 (35.0) 23 (67.6) 30 (78.9)
Met/Met 33 (20.1) 10 (6.2) 5 (14.7) 6 (15.8)
Allelew
Val 183 (55.8) 244 (76.2) 35 (51.5) 34 (44.7)
Met 145 (44.2) 76 (23.8) 33 (48.5) 42 (55.3)
*HC versus AD: w2(2)=28.258, P<0.0001; HC versus DLB:
w2(2)=4.405, P=0.111; HC versus PiD: w2(2)=13.786, P=0.001.
wHC versus AD: w2(1)=30.163, P<0.0001; HC versus DLB:
w2(1)=0.425, P=0.514; HC versus PiD: w2(1)=3.034, P=0.082.
AD indicates Alzheimer disease; BDNF, brain-derived neurotrophic
factor; DLB, dementia with Lewy bodies; HC, healthy control; PiD, Pick
disease.
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divided into subgroups according to the presence of the e4
allele (1 or 2) and the presence of the Val allele (1 or 2).
Genotypes containing both the e4 and BDNF Val alleles
occurred more frequently in all types of dementias than in
HC. Moreover, in the PiD group, the frequency of these
genotypes was outstandingly high (AD: 36.9%, DLB:
47.1%, PiD: 63.2%, and HC: 10.4%). The OR for the
presence of both the e4 and BDNF Val alleles in the AD
group was 14.46 [95% conﬁdence interval (CI): 5.10-40.98],
in the DLB group was 7.84 (95% CI: 1.97-31.13), and in the
PiD group was 35.29 (95% CI: 4.35-286.24), as compared
with patients with neither the e4 nor the BDNF Val alleles.
As in AD, the OR 14.46 (95% CI: 5.10-40.98) for the
occurrence of the e4 and BDNF Val alleles was much
higher than the OR 2.08 (95% CI: 0.47-9.29) for the
presence of e4 without the Val allele, we propose a
synergistic eﬀect of the 2 SNPs on risk for AD. In the
case of DLB and PiD, we found that the OR for the
presence of both alleles [DLB: OR 7.84 (1.98-31.13); PiD:
OR 35.29 (4.35-286.24)] was also higher as compared with
the OR for having the e4 and lacking the Val allele [DLB:
OR 2.08 (0.294-14.766); PiD: OR 15.63 (1.58-154.28)].
Therefore, we suggest that the presence of the Val allele, in
combination with the e4 allele, might play a role in the risk
for DLB and PiD.
DISCUSSION
Our data revealed that the Val66Met polymorphism of
the BDNF gene may be implicated in the susceptibility to
AD, as we have found that the Val/Val genotype and the
Val allele occurred with signiﬁcantly higher frequency in
AD than in HC. Japanese and Italian studies have also
reported this association,9,13 although another Japanese
study and a Spanish study failed to ﬁnd the same
results.12,14 The frequency of occurrence of the Val allele
in the Hungarian AD group in this study was similar to the
data published for Italian and Spanish populations
(Hungarian: 76%; Italian: 78%; and Spanish: 79%).
Although in the Japanese population, Matsushita and co-
workers13 reported 61%, Akatsu et al14 reported 57%
frequency for the occurrence of the Val allele in AD. In
contrast to the ﬁndings in the AD group, the distribution of
the Val allele among the Hungarian HC probands was
closer to the results found in the Japanese HC groups
(Hungarian: 56%; Japanese13: 56%; Japanese14: 57%; vs.
Italian: 70%; Spanish: 81%). According to these ﬁndings,
the BDNF Val66Met polymorphism is highly heteroge-
neous among the diﬀerent ethnic populations, even within
Europe.
BDNF is important for memory-related hippocampal
processes. The functional Val66Met polymorphism of
TABLE 3. ApoE Genotype and Allele Frequencies in Different
Groups










e2/e2 2 (1.2) — — —
e2/e3 24 (14.7) 10 (6.2) 1 (2.9) 2 (5.3)
e2/e4 — 1 (0.6) — 7 (18.4)
e3/e3 113 (68.9) 87 (54.4) 15 (44.2) 7 (18.4)
e3/e4 21 (12.8) 48 (30.0) 17 (50.0) 20 (52.6)
e4/e4 4 (2.4) 14 (8.8) 1 (2.9) 2 (5.3)
Allelew
e2 28 (8.5) 11 (3.4) 1 (1.5) 9 (11.8)
e3 271 (82.6) 232 (72.5) 48 (70.6) 36 (47.4)
e4 29 (8.9) 77 (24.1) 19 (27.9) 31 (40.8)
*HC versus AD: w2(5)=28.220, P<0.0001; HC versus DLB:
w2(4)=26.469, P<0.0001; HC versus PiD: w2(5)=70.951, P<0.0001.
wHC versus AD: w2(2)=32.076, P<0.0001; HC versus DLB:
w2(2)=21.803, P<0.0001; HC versus PiD: w2(2)=53.233, P<0.0001.
AD indicates Alzheimer disease; ApoE, apolipoprotein E; DLB,
dementia with Lewy bodies; HC, healthy control; PiD, Pick disease.
TABLE 4. Interaction Between ApoE e4 and BDNF Val Alleles in Different Groups
No. Persons (Frequency %)
HC AD
ApoE e4 BDNF Val n=164 n=160 OR 95% CI P
+ + 17 (10.4) 59 (36.9) 14.461 5.103-40.979 <0.0001
+  8 (4.9) 4 (2.5) 2.083 0.467-9.288 0.336
 + 114(69.5) 91 (56.8) 3.326 1.309-8.452 0.012
  25 (15.2) 6 (3.8) Reference
HC DLB
n=164 n=34
+ + 17 (10.4) 16 (47.1) 7.843 1.976-31.128 0.003
+  8 (4.9) 2 (5.9) 2.083 0.294-14.766 0.463
 + 114(69.5) 13 (38.2) 0.950 0.252-3.586 0.940
  25 (15.2) 3 (8.8) Reference
HC PiD
n=164 n=38
+ + 17 (10.4) 24 (63.2) 35.294 4.352-286.241 0.001
+  8 (4.9) 5 (13.1) 15.625 1.582-154.279 0.019
 + 114(69.5) 8 (21.1) 1.754 0.210-14.666 0.604
  25 (15.2) 1 (2.6) Reference
The reference category is HC.
Model: w2(9)=82.344, P<0.0001.
AD indicates Alzheimer disease; ApoE, apolipoprotein E; BDNF, brain-derived neurotrophic factor; CI, conﬁdence interval; DLB, dementia with Lewy
bodies; HC, healthy control; PiD, Pick disease; OR, odds ratio.
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BDNF can inﬂuence the activity-dependent BDNF secre-
tion, thus it can impact on hippocampal activity. Egan et
al10 reported impaired episodic memory in Met allele
carrier healthy probands and found that neurons trans-
fected with BDNFMet showed lower depolarization-induced
secretion of BDNF. These results are consistent with
another study that demonstrated reduced hippocampal
activity during declarative memory processing in Met allele
carrier probands.11 According to our ﬁndings and other
association studies, the Val allele is associated with AD.12,13
The decreased BDNF level in AD reported by several
studies7,28 can be the result of the neurodegenerative
processes, the loss of neurons producing BDNF, and
therefore, it can be independent of the BDNF genotype.
In the early stage of AD, higher BDNF level was measured
than in HC,29 which can be inﬂuenced by the level of the
regulated secretion of BDNF, and therefore, the BDNF
Val66Met genotype. A possible explanation of the contra-
dictory observations and the role of the BDNF Val66Met
polymorphism in AD need further investigation.
According to our data, the BDNF Val66Met poly-
morphism does not confer susceptibility to DLB, and these
results are in agreement with a Japanese study.14 The
BDNF Val66Met genotype frequencies did not diﬀer
signiﬁcantly in the Japanese study, nor in this study. The
distribution of the Val allele in the Hungarian DLB and HC
groups was similar to the Japanese data (Hungarian DLB:
52%; Japanese DLB 60%; Hungarian HC: 56%; and
Japanese HC: 55%).
This is the ﬁrst report on BDNF Val66Met poly-
morphism in PiD. The heterozygous Val/Met genotype
occurred in PiD with outstandingly high frequency, which
was statistically signiﬁcant compared with HC, but we have
not found signiﬁcant diﬀerence in the distribution of BDNF
alleles. The small sample size for DLB and PiD can
inﬂuence the results of the statistical analyses and can
explain the wide CIs; therefore, this is a study generating
hypothesis and further investigations are required.
It has been shown that BDNFMet could alter the
intracellular distribution and activity-dependent secretion
of BDNFVal. The BDNFVal/BDNFMet heterodimers coex-
pression results in decreased secretion,10 which can be a
possible explanation for our ﬁndings in PiD. Memory
impairment has been observed in probands having the Val/
Met genotype.10,11 As the activity-dependent release of
BDNF modulates synaptic transmission and neural plasti-
city,30 this behavioral deﬁcit may be attributable to the
decreased secretion of BDNFVal/BDNFMet heterodimers.
We found that the ApoE e4 allele was signiﬁcantly
overrepresented in AD, DLB, and PiD, as compared with
the HC group. These results are in line with our former
ﬁndings for the AD group in the Hungarian popula-
tion26,31,32 and with results on other ethnic groups.33–35
Despite the relatively low number of DLB and PiD
patients, our ﬁndings can provide important data, as we
have a found signiﬁcant diﬀerence in the distribution of the
e4 allele in DLB and PiD, as compared with HC. The
frequency of the e4 allele was even higher in PiD than in
AD. These ﬁndings conﬁrm the results of genetic and
epidemiologic studies that have reported that the e4 allele is
the most important known risk factor for late-onset familial
and sporadic forms of AD and other dementias. The
presence of the e4 allele increases the risk and reduces the
age for the onset of dementia, in contrast to the possession
of the e2 allele that has a protective eﬀect. ApoE e4 isoform
has been demonstrated to negatively inﬂuence and intensify
the biochemical disturbances of AD, including b-amyloid
deposition, tangle formation, neuronal cell death, dysfunc-
tion of lipid homeostasis, and cholinergic signaling.15
In summary, our ﬁndings indicate that the BDNF Val
allele may confer susceptibility to AD, whereas the BDNF
Val/Met genotype increases the risk for PiD. Genotypes
containing both the ApoE e4 and BDNF Val alleles were
overrepresented in all investigated dementias, and the
comparison of the ORs for having both e4 and Val alleles
and for having only e4 without the Val allele might reveal a
possible role of these risk factors in the pathogenesis of AD,
DLB, and PiD.
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 Introduction 
 Alzheimer’s disease (AD), dementia with Lewy bodies 
(DLB) and Pick’s disease (PiD) are neurodegenerative 
disorders associated with abnormal protein aggregation 
and inclusion body formation. AD pathology is charac-
terized by the presence of senile plaques composed of am-
yloid-  42 (A  42 ) and neurofibrillary tangles containing 
hyperphosphorylated tau protein  [1] . DLB is a neurode-
generative condition associated with abnormal aggrega-
tion of   -synuclein, termed Lewy bodies  [2] . The term 
‘Pick’s disease’ is restricted to cases showing lobar atro-
phy with Pick bodies, composed of numerous randomly 
oriented hyperphosphorylated tau fibrils  [3] , and PiD is 
included in the nomenclature of frontotemporal demen-
tia  [4] . Vascular dementia (VD) results from various cere-
brovascular diseases leading to cognitive impairment 
which depends on the severity and location of lesions 
 [5] .
 Alpha-7 nicotinic acetylcholine receptors (  7 nAChRs) 
are homopentamer, ligand-gated cationic channels. They 
are widely expressed in the central nervous system with 
high levels in the regions relevant to memory functions 
and involved in processing of sensory information, such 
as the hippocampus  [6] . It has been demonstrated that 
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 Abstract 
 We tested the hypothesis whether the partially duplicated 
variant of   7 nicotinic acetylcholine receptor subunit gene 
(CHRFAM7A) 2-bp deletion (–2 bp) polymorphism and apoli-
poprotein E (ApoE)   4 allele confer susceptibility to Alzhei-
mer’s disease (AD), dementia with Lewy bodies (DLB), Pick’s 
disease (PiD) and vascular dementia (VD). The study includ-
ed 175 AD, 35 DLB patients, 38 PiD, 96 VD and 175 healthy 
control (HC) probands. The CHRFAM7A genotype without 
the –2 bp allele was significantly over-represented in AD 
(p = 0.011), DLB (p = 0.001) and PiD (p  ! 0.0001) compared to 
HC, but there were no statistical differences in VD (p = 0.407) 
compared to HC. We confirmed again that the ApoE   4 allele 
is a risk factor for dementias. The –2 bp polymorphism of 
CHRFAM7A can be implicated in AD, DLB and PiD. However, 
it is unlikely that it plays an important role in the pathogen-
esis of VD.  Copyright © 2009 S. Karger AG, Basel 
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A  42 binds to   7 nAChR with high affinity and they both 
are present in senile plaques  [7] . Their interaction alters 
several neurochemical processes, including Ca 2+ homeo-
stasis and acetylcholine release, and thereby modulates 
neuronal physiological functions implicated in memory 
processes. Chronic inhibition of cholinergic signaling by 
A  42 could contribute to the cognitive deficits associated 
with AD  [8] . In an experimental system, A  42 effectively 
induced tau phosphorylation via   7 nAChR that could be 
decreased by   7 nAChR antagonists. A  42 –  7 nAChR 
interaction activates mitogen-activated cascade protein, 
which is a tau protein kinase  [9] . Although the   7 nAChR-
mediated and A  42 -induced tau phosphorylation seemed 
to be a normal reversible cellular response, the above 
mentioned findings suggest that   7 nAChR may be im-
plicated in neuropathological conditions associated with 
abundant A  42  and/or abnormal functions of tau protein. 
Abnormal   7 nAChR physiology and loss of neurons ex-
pressing   7 nAChR may contribute to memory and cog-
nition impairment  [9] .
 The   7 nAChR subunit gene (CHRNA7) is located
in the highly duplicated 15q13–q14 region implicated
in several neuropsychiatric disorders, including schizo-
phrenia and bipolar affective disorder. The CHRNA7 
gene is duplicated from exon 5 to 10 with  1 99% identi-
ty at the nucleotide level  [10, 11] . The partially duplicat-
ed CHRNA7 and 4 novel exons D–A originated from
the FAM7A gene form a hybrid gene (CHRFAM7A). 
CHRFAM7A is not present on every human chromosome 
and some individuals lack 1 (30%) or both (5%) copies 
 [11] . A 2 bp deletion (–2 bp) polymorphism at position 
497–498 in exon 6 was identified, which is specific to 
CHRFAM7A and does not occur in CHRNA7  [10] . The 
–2 bp deletion causes a frameshift, introducing a stop co-
don within exon 6, and therefore a truncation in a puta-
tive gene product. Since CHRFAM7A is reported to be 
expressed as mRNA, possible regulatory effects should 
also be considered. Recent findings of Flomen et al.  [12] 
suggested that CHRFAM7A exists in 2 orientations (ei-
ther direct or inverted orientation relative to CHRNA7) 
and this inversion polymorphism is in a linkage disequi-
librium with the –2 bp polymorphism.
 Apolipoprotein E (apoE) is involved in lipid transport 
and metabolism. In addition, it plays specific roles in the 
central nervous system including neuronal development, 
regeneration and certain neurodegenerative processes. 
Polymorphism of the ApoE gene located on chromosome 
19 determines 3 isoforms (  2,   3,   4) with different con-
formation and lipid-binding properties  [13] . The   3 and 
  2 isoforms bind primarily to high-density lipoprotein, 
while   4 prefers very-low-density lipoprotein and is less 
effective in cholesterol transport. ApoE   4 increases the 
risk and reduces the age of the onset in AD  [14] . Further-
more,   4 carriers have an increased risk of other demen-
tias, such as DLB and PiD  [15, 16] .
 Liou and co-workers (2001) failed to find association 
between the CHRFAM7A –2 bp polymorphism and AD, 
investigating a relatively low number of cases in an Asian 
population  [17] . According to our knowledge, the –2 bp 
polymorphism of CHRFAM7A has not been studied in 
any other dementias. The aim of our study was to provide 
data about ApoE and CHRFAM7A –2 bp polymorphisms 
in different dementias in the Hungarian Caucasian pop-
ulation. We tested the hypothesis whether the ApoE   4 
and the CHRFAM7A wild-type alleles confer susceptibil-
ity to dementias, while the presence of the CHRFAM7A 
–2 bp allele can have a protective effect against AD, VD 
and the rare-occurring DLB and PiD, from which very 
few genetic association data are available. In addition, 
we investigated the interaction between the ApoE and 
CHRFAM7A polymorphisms in the above mentioned 
diseases.
 Materials and Methods 
 Probands were all Caucasians living in Hungary. The study 
included 175 AD patients from the Memory Clinic, Department 
of Psychiatry, University of Szeged, who met the NINCDS/
ADRDA criteria for probable AD  [18] . The clinical diagnosis of 
probable AD was based on the history of the probands, psychiat-
ric and neurological examination, basic clinical tests such as the 
Mini-Mental State Examination (MMSE) and the Hachinsky, 
Clock Drawing and Verbal fluency scores, as well as brain CT or 
MRI imaging. Probands all had experienced a progressive loss of 
cognitive functions (in more than 2 cognitive domains indicative 
of cortical dysfunction) for at least 1 year with memory loss as the 
most significant symptom. The CT or MRI images for AD pa-
tients revealed generalized or temporal lobe atrophy. However, 
cerebrospinal amyloid and tau levels were not evaluated.
 Twenty DLB cases were selected retrospectively on the basis of 
the postmortem neuropathological examination. In these cases, 
the Consortium on DLB International Workshop’s neuropatho-
logical criteria of DLB was considered  [19] . The remaining 15 
probable DLB probands were patients of the Semmelweis Medical 
University, Department of Psychiatry and Psychotherapy, Buda-
pest. Their clinical diagnoses were established according to the 
McKeith criteria  [20] . None of them had confirmed autopsy diag-
noses since all of them are still alive.
 The 38 PiD cases were all carefully selected autopsy cases from 
the tissue bank at the Department of Neuropathology, National 
Institute of Psychiatry and Neurology, Budapest. The clinical di-
agnoses were verified by postmortem examination. Besides the 
marked frontotemporal atrophy, sections from different parts of 
the cerebral cortex and basal ganglia were stained with cresyl vio-
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let and with the Bielschowsky silver method; Pick cells and Pick 
bodies were seen.
 The 96 patients of VD were clinically diagnosed as probable 
VD cases according to the criteria of ICD-10  [21] , and the NINDS-
AIREN International Workshop’s diagnostic criteria for research 
studies  [22] . All VD patients had small-vessel disease, character-
ized by subcortical multiple lacunar infarcts around the lateral 
ventricles in both hemispheres, revealed by brain MRI evaluation. 
Other types of VD cases with cortical or strategic infarcts were 
not involved in the study.
 The 175 age-matched healthy control (HC) probands were se-
lected from spouses of patients at the Memory Clinic, Depart-
ment of Psychiatry, University of Szeged. HCs were medication-
free, lacked any significant medical illnesses and had Hachinsky 
scores  ! 4. Informed consent was obtained from the living sub-
jects included in this study and all protocols were approved by the 
local ethical committee.
 MMSE scores  ! 24 were considered characteristic of demen-
tia. MMSE scores in the HC group were always  1 28 points (mean: 
29.1  8 0.9) and none had verified symptoms of dementia. For the 
PiD group, we have no MMSE data. The MMSE mean score in the 
AD group was 17.9  8 6.1, in the DLB group, it was 18.5  8 5.8, 
and in the VD group, it was 19.7  8 5.7. The characteristics of the 
probands are presented in  table 1 .
 DNA was extracted from peripheral blood leukocytes accord-
ing to a standard Roche procedure kit. In the PiD cases, DNA was 
extracted from paraffin-embedded brain tissues by E.Z.N.A. kit 
(PeqLab Biotechnologie GmbH, Erlangen, Germany). ApoE ge-
notyping was made by PCR as described earlier  [23] . Genotyping 
of the CHRFAM7A –2 bp polymorphism was performed using 
PCR amplifications, followed by polyacrylamide gel electropho-
resis with ethidium bromide staining  [24] . We focused on the de-
letion polymorphism of the CHRFAM7A and did not investigate 
the copy number or the inversion polymorphisms; therefore, we 
determined 3 groups. The genotype lacking the 2 bp deletion was 
designated genotype 1, the genotype having 1 copy of the –2 bp 
allele was designated genotype 2, and the genotype with 2 copies 
of the –2 bp allele was designated genotype 3.
 The ApoE and the CHRFAM7A genotype frequencies were 
compared with the Fisher’s exact and the Pearson   2 tests. A mul-
tinomial logistic regression model was used to test for the interac-
tion between the ApoE   4 allele and CHRFAM7A wild genotype 
(without the –2 bp allele). The significance level was set at p  !  0.01. 
SPSS 15.0 was used for all computer statistical analyses.
 Results 
 CHRFAM7A genotype frequencies are presented in 
 table 2 . Genotype 1 was significantly over-represented in 
AD, DLB and PiD compared to HC. Moreover, the fre-
quency of genotype 1 in PiD was outstandingly high (AD: 
36.0%, DLB: 54.3%, PiD: 76.3%, HC: 24.0%). The fre-
quency of genotype 3 was significantly lower in AD and 
in PiD than in the HC group (AD: 12.6%, PiD: 2.6%, HC: 
22.3%), but it occurred in DLB and in VD with similar 
frequency compared to the HC group (DLB: 20.0%, VD: 
21.9%). The differences were statistically significant in 
the DLB (p = 0.001) and PiD (p  ! 0.0001) groups, and 
marginally significant in the AD (p = 0.011) group com-
pared to HC, as we set the significance level to 0.01. Com-
parison of the CHRFAM7A genotype frequencies be-
tween VD and HC showed no statistically significant dif-
ference (p = 0.407), although genotype 1 occurred more 
frequently in the VD group than in the HC group (VD: 
31.2%, HC: 24.0%).
 The distribution of the ApoE genotypes and alleles are 
presented in  table 3 . Among the patients with dementia, 
no ApoE   2/  2 carriers were detected and even in the HC 
group, only 2 cases were found. The ratio of the   3/  4 car-
riers was significantly higher in all groups of dementia 
than in the HC group; furthermore, in the DLB and PiD 











Age, years 71.788.5 74.089.2 76.787.2 70.088.3 75.389.8
Male/female 77/98 59/116 15/20 12/26 37/59
MMSE, scores 29.180.9 17.986.1 18.585.8 – 19.785.7
Table 1. Characteristics of the probands













1 42 (24.0) 63 (36.0) 19 (54.3) 29 (76.3) 30 (31.2)
2 94 (53.7) 90 (51.4) 9 (25.7) 8 (21.1) 45 (46.9)
3 39 (22.3) 22 (12.6) 7 (20.0) 1 (2.6) 21 (21.9)
* HC versus AD: 2(2) = 9.025, p = 0.011; HC versus DLB = 
Fisher’s exact test: p = 0.001; HC versus PiD: Fisher’s exact test:
p < 0.0001; HC versus VD: 2(2) = 1.797, p = 0.407.
Percentages are shown in parentheses.
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2/2 2 (1.1) – – – –
2/3 25 (14.3) 11 (6.3) 1 (2.9) 2 (5.3) 10 (10.4)
2/4 – 3 (1.7) – 7 (18.4) 3 (3.1)
3/3 125 (71.4) 91 (52.0) 16 (45.7) 7 (18.4) 58 (60.4)
3/4 19 (10.9) 56 (32.0) 17 (48.5) 20 (52.6) 23 (24.0)
4/4 4 (2.3) 14 (8.0) 1 (2.9) 2 (5.3) 2 (2.1)
Allele**
2 29 (8.3) 14 (4.0) 1 (1.4) 9 (11.8) 13 (6.8)
3 294 (84.0) 249 (71.1) 50 (71.4) 36 (47.4) 149 (77.6)
4 27 (7.7) 87 (24.9) 19 (27.2) 31 (40.8) 30 (15.6)
* HC versus AD: 2(5) = 39.605, p < 0.0001; HC versus DLB: Fisher’s exact test: p < 0.0001; HC versus PiD: 
Fisher’s exact test: p < 0.0001; HC versus VD: 2(5) = 15.275, p = 0.009.
** HC versus AD: 2(2) = 40.541, p < 0.0001; HC versus DLB: Fisher’s exact test: p < 0.0001; HC versus PiD: 
Fisher’s exact test: p < 0.0001; HC versus VD: 2(2) = 8.365, p = 0.015.
Percentages are shown in parentheses.





HC (n = 175) AD (n = 175) OR 95% CI p*
+ + 7 (4.0%) 22 (12.6%) 6.028 2.438–14.902 <0.0001
+ – 16 (9.1%) 51 (29.1%) 6.114 3.220–11.609 <0.0001
– + 35 (20.0%) 41 (23.4%) 2.247 1.300–3.883 0.004
– – 117 (66.9%) 61 (34.9%) reference
HC (n = 175) DLB (n = 35)
+ + 7 (4.0%) 9 (25.7%) 21.490 6.170–74.848 <0.0001
+ – 16 (9.1%) 9 (25.7%) 9.402 3.076–28.740 <0.0001
– + 35 (20.0%) 10 (28.6%) 4.776 1.693–13.471 0.003
– – 117 (66.9%) 7 (20.0%) reference
HC (n = 175) PiD n = 38
+ + 7 (4.0%) 21 (55.2%) 351.000 41.043–3001.733 <0.0001
+ – 16 (9.1%) 8 (21.1%) 58.500 6.859–498.957 <0.0001
– + 35 (20.0%) 8 (21.1%) 26.743 3.233–221.216 0.002
– - 117 (66.9%) 1 (2.6%) reference
HC (n = 175) VD (n = 96)
+ + 7 (4.0%) 10 (10.4%) 3.482 1.252–9.682 0.170
+ – 16 (9.1%) 18 (18.8%) 2.742 1.292–5.820 0.009
– + 35 (20.0%) 20 (20.8%) 1.393 0.732–2.652 0.313
– – 117 (66.9%) 48 (50.0%) reference
The reference category is HC. Model: 2(12) = 122.352, p < 0.0001. 
* Wald 2 test.
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48.5%, PiD: 52.6%, VD: 24.0%, HC: 10.9%). The   4 allele 
was significantly over-represented in AD, DLB and PiD 
compared to HC (AD: 24.9%, p  ! 0.0001; DLB: 27.2%, 
p  ! 0.0001; PiD: 40.8%, p  ! 0.0001). Comparison of   4 
allele frequencies between VD and HC showed a mar-
ginally significant difference (VD: 15.6%, HC: 7.7%, p = 
0.015). The frequency of the occurrence of the   4 allele in 
PiD cases was extremely high, not only compared to HC, 
but also to other dementias.
 The genotype frequencies of both ApoE and CHRFA-
M7A polymorphisms in the PiD group differed signifi-
cantly from the genotype distribution in the AD and VD 
groups (CHRFAM7A genotypes: PiD vs. AD: p  ! 0.0001; 
PiD vs. VD: p  ! 0.0001, and ApoE genotypes: PiD vs. AD: 
p  ! 0.0001; PiD vs. VD: p  ! 0.0001).
 Table 4 summarizes the frequencies and odds ratios 
(OR) for the interaction between ApoE   4 allele and 
CHRFAM7A genotype 1 in different groups. Simultane-
ous presence of ApoE   4 allele and CHRFAM7A geno-
type 1 occurred more frequently in all types of dementia 
compared to HC (AD: 12.6%, DLB: 25.7%, PiD: 55.2%, 
VD: 10.4%, HC: 4.0%).
 The ORs for the presence of   4 allele with or without 
the CHRFAM7A genotype 1 were similar in AD and VD 
( table 4 ); therefore, it is unlikely that the combination of 
these genetic variants would be involved in AD or VD. In 
DLB and PiD, however, the OR for the presence of both 
risk factors was much higher than the OR for the posses-
sion of   4 allele without CHRFAM7A genotype 1 ( ta-
ble 4 ), suggesting that the simultaneous occurrence of   4 
allele and CHRFAM7A genotype 1 can enhance the risk 
for the development of DLB and PiD.
 Discussion 
 Our major finding was that the CHRFAM7A genotype 
without the –2 bp allele was significantly over-represent-
ed in AD, DLB and PiD compared to HC and we further 
confirmed that the ApoE   4 allele is a risk factor for de-
mentias. The simultaneous occurrence of these 2 risk fac-
tors was over-represented in the DLB and PiD groups.
 The CHRFAM7A genotype 1 occurred with signifi-
cantly higher frequency in the AD, DLB and PiD groups 
than in the HC group. The absence of the –2 bp allele in 
the DLB group and especially in the PiD group occurred 
even more frequently than in the AD group; however, the 
small sample size for DLB and PiD can affect the results 
of the statistical analyses. The CHRFAM7A genotype fre-
quencies showed no significant differences between the 
VD and HC groups. According to these results, the par-
tially duplicated variant of the   7 nAChR subunit gene, 
expressed together with the 4 exons from the FAM7A 
gene, can be a strong candidate gene for neurodegenera-
tive disorders associated with abnormal protein aggrega-
tions. There may be a functional relationship between 
A  42 ,   7 nAChR and tau protein, since it has been 
 reported that an A  42 –  7 nAChR interaction can acti-
vate tau phosphorylation  [9] . This relationship can 
be the common feature by which genetic variants of 
CHRFAM7A can influence the risk either for AD, DLB 
or PiD. A  42 is the major component of senile plaques 
implicated in AD and DLB, and the hyperphosphorylat-
ed tau protein is the main constituent of neurofibrillary 
tangles in AD brains and Pick bodies occurring in PiD.
 The duplicated   7 nAChR exons (CHRNA7 5–10) and 
the 4 novel exons (FAM7A D–A) are transcribed togeth-
er, but there is no evidence whether this transcript is 
translated or not  [10, 11] . It is unlikely that this hybrid 
gene functions as a nicotinic receptor due to the absence 
of signal peptide, glycosylation site and part of the ligand-
binding site encoded by exons 1–4  [25] . It is possible, 
however, that if CHRFAM7A is translated, the gene prod-
uct is able to interact with   7 polypeptide since most of 
the contact regions are encoded in exons 5–10  [11] . The 
mechanisms by which the –2 bp allele variant of dupli-
cated exon 6 decrease the risk of dementias remain to be 
established. The 2 bp deletion results in a stop codon 
within exon 6; therefore, the putative translational prod-
uct will be truncated. A possible explanation could be 
that the wild-type CHRFAM7A gene product may alter 
the normal assembly of the   7 nAChR, which could be 
avoided by the truncated gene product  [11] .
 Our study demonstrates the association of the ApoE 
  4 allele with AD, DLB, PiD and VD. These results in the 
AD and VD groups are in line with our former findings 
in the Hungarian population  [23, 26–28] and with results 
on other ethnic groups  [29, 30] . However, in the case of 
VD, no correlation between the   4 allele and VD has also 
been reported  [31, 32] . The apparently contradictory data 
can be explained by the lack of clear-cut diagnostic crite-
ria and great clinical heterogeneity of this disorder. Al-
though in this study a relatively low number of DLB and 
PiD probands were included, our findings can provide 
important data, since we have found a statistically sig-
nificant difference in the occurrence of the   4 allele in 
DLB and in PiD compared to HC. The frequency of the 
  4 allele was even higher in PiD than in AD, which is in 
agreement with our former result  [16] .
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